



Preclinical development of 
adoptive T-cell immunotherapy 
for EBV-associated diseases 








A thesis submitted to 
The University of Birmingham 
for the degree of 






                    
           School of Cancer Sciences 
           Medical and Dental Sciences 
                                                                                               University of Birmingham  
















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 








A significant number of patients requiring adoptive T-cell therapy (ATCT) need to resort 
to third party donors; we aimed to find ways to optimise ATCT from third party donors in 
EBV-associated diseases.  
Firstly, we evaluated the T-cell response to 29 EBV-restricted peptides in a cohort of 100 
healthy donors. For each peptide we found at least one high-responding donor. Also, we 
compared the efficacy of different separation techniques. These results support the setting 
up of a registry of third party donors, to provide fresh EBV-specific T cells for ATCT.  
Secondly, we investigated the mechanisms generating T memory stem cells (TSCM), 
which are considered most suitable for ATCT.  We demonstrated that homeostatic 
cytokines revert recently differentiated CD8+ memory T cells from cord blood (CB) to 
cells with a TN-like phenotype (TNrev) and TSCM-like characteristics.  
Finally, we compared phenotype and function of CD8+ T cells from peripheral blood and 
CB, after transduction of an EBV-specific TCR. Transduction efficiency, growth kinetics 
and cytolytic activity were comparable. However, TCR-transduced CB T cells showed 
less differentiated phenotype, increased multi-cytokine expression, and lacked expression 
of the senescence marker CD57. These data suggest that survival of engineered T cells in 
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1.1. THE EPSTEIN-BARR VIRUS 
  
 
1.1.1. CLASSIFICATION AND STRUCTURE 
The analysis of molecular sequences in different virus strains suggests that 
Herpesviridae appeared during the Jurassic period, about 200 million years ago 
(McGeoch et al., 1995). Since then, they have evolved to infect, besides reptiles, also 
birds and mammals. 
Nine different species of Herpesviridae can cause diseases in humans, but the most 
common pathogens are the Herpes Simplex Virus, the Varicella Zoster Virus, the 
Cytomegalovirus (CMV), and the Epstein-Barr virus (EBV).  
The EBV, also called human herpesvirus 4, belongs to the subfamily 
Gammaherpesvirinae, genus Lymphocryptovirus, and was first described in 1964 by 
Michael Epstein, Albert Achong and Yvonne Barr in lymphoblastoid cells from a patient 
with the endemic form of Burkitt’s lymphoma (Epstein et al., 1964).  There are two 
types of EBV: Type 1 is the most common, being present in Europe, America and Asia, 
and in Africa it coexists with Type 2, which is also present in New Guinea (Zimber U et 
al., 1986). The two types differ in their nuclear antigens and in their ability to transform 
infected cells, Type 1 being more effective than Type 2 (Odumade et al., 2011). Several 
different strains of EBV have been identified so far, the first strain to have the genome 
sequenced being B95-8 (Baer et al., 1984). Although overall sequence similarities 
between strains can go down to 95%, the different genomes share common features: 
they are about 170 kb in length, and code for at least 86 different proteins (Kwok et al., 
2012). The best known open reading frames and their products are listed in Table 1. 
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 Table 1.1. Examples of EBV genes and gene products.  
 (Various authors, 2012) 
      
   
 
Some latent genes are not translated, such as the Epstein-Barr virus-encoded RNA 
(EBER) 1 and 2, and at least 17 micro-RNAs are also encoded (Cai et al., 2006). 
The linear, double stranded DNA is wrapped around an annular-shaped protein core that 
is contained within a capsid resulting from the assembly of 150 hexameric and 12 
 
 4 
pentameric capsomers (Germi et al., 2012). The capsid is inside a protein tegument that 
is surrounded by a membrane with virus-encoded glycoprotein spikes (Figure 1.1).     
 
      
 
Figure 1.1.  Scheme of structure and genome of EBV. 
OriP and OriLyt indicate the origins of latent and lytic replication respectively. The 
location of some genes is shown: in green are latent genes, in yellow, orange and red are 





1.1.2. MECHANISMS OF CELL INFECTION 
 
1.1.2.1. VIRUS ENTRY 
The virus is primarily spread through saliva, rarely through semen or blood. The main 
targets of EBV primary infection are initially the epithelial cells of oronasopharynx, and 
then B lymphocytes, but the virus uses different strategies for attaching to and entering 





Figure 1.2. Models of EBV entry in human cells.  
The different steps that have been hypothesized for virus entry are shown for B 
lymphocytes (A) and for epithelial cells (B). Initially, binding of a viral ligand to a 
cellular receptor delivers a phagocytotic signal (1). Other interactions strengthen the 
bond (2). Further interactions start the fusion process (3). Finally the endosomal 




In B lymphocytes, glycoprotein (gp) 350/220 on virus envelope binds to complement 
receptor 2 (CR2) on cell membrane (Frade R et al., 1985), inducing capping of CR2 and 
triggering an endocytotic signal (Tanner et al., 1987). Further interactions stabilize the 
bound and allow the virus to come closer to the cell membrane (Hutt-Fletcher, 2007). 
These interactions involve binding of viral proteins gHgL, gB and gp42 with the human 
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leukocyte antigen (HLA) Class II molecules, either HLA-DR, HLA-DQ or HLA-DP, on 
the cell membrane. The mechanisms of attachment of EBV to epithelial cells are more 
debated, since it is unclear whether all epithelial cells express CR2, and at what level, 
moreover they do not express HLA Class II molecules. Interactions of viral proteins 
BMRF and gHgL with a still unknown receptor and integrins and v on the 
cell membrane have been suggested (Hutt-Fletcher., 2007; Xiao et al., 2007). Whichever 
is the underlying mechanism, EBV attachment to a target cell results in fusion of the 
viral envelope with the endosomal membrane and release of the tegumented capsid into 
cell cytosol.  
Although EBV infects predominantly B lymphocytes and epithelial cells, in some 
instances it was found to be able to infect also natural killer (NK) cells, T lymphocytes 
and smooth myocytes (Rickinson et al., 2007). It can also infect monocytes (Savard et 
al., 2000), albeit this ability seems to be restricted mainly to viruses generated in 
epithelial cells (Guerreiro-Cacais et al., 2004), and possibly follicular dendritic cells 
(DCs) (Rickinson et al., 2007).  
 
1.1.2.2. VIRUS REPLICATION, LYTIC AND LATENT PROGRAMMES 
The downstream events, leading to entry of the EBV genome into the nucleus, have still 
to be elucidated, and might only be inferred from comparison with other herpesviridae. 
Once reached the nucleus, the EBV genome can follow two different replication 
strategies: it can either start a lytic cycle or remain latent, depending on the transcription 
pattern involved (Figure 1.3). During the lytic phase viral genes regulating transcription, 
transduction and coding for structural proteins are active. Immediate early, early and late 
lytic antigens are sequentially expressed. Transcription from the linear DNA starts in B 
lymphocytes 10-12 hours after infection, and circularization occurs after 6 more hours 
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(Arvin et al., 2007), but amplification of the newly produced episomes requires more 
than a week (Longnecker and Neipel, 2007). The transcription of the immediate early 
genes leads the host cell to start the S phase of the cell cycle 24-48 hours after infection, 
the following gene products induce continuous proliferation of the infected B cell, and 





Figure 1.3. The different phases of the EBV life cycle. 
During lytic phase all the genes are transcribed, starting a cascade of events that results 
in EBV genome replication, viral structural protein synthesis, and virion assembly. 




During lytic replication the viral genome is amplified hundreds of times, all the proteins 
are transcribed, and new virions are assembled and released. This event takes place 
during acute infections, but virions can be occasionally found in asymptomatic carriers, 
indicating a sporadic activation of the lytic programme (Tsurumi et al., 2005). 
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Contrary to the lytic phase, the latent phase comes up with different transcription 
programmes, from 0 to III, depending on host cell factors. The different programmes 
activate different promoters, involve the expression of different genes, occur in different 
subtypes of normal B lymphocytes, and have different effects on the host cell (Table 
1.2). 
 
Table 1.2. The different latency programmes in B cells. 








Latency 0 (true latency) EBERs Peripheral memory Allow lifetime persistence 
Latency I  EBERs, EBNA-1 Dividing peripheral 
memory 
Allow virus in latency 
programme cells to divide 
Latency II (default) LMP-1, LMP-2A, EBNA-1, EBERs Germinal centre Differentiate activated        
B cell into memory 
Latency III (growth) LMP-1, LMP-2A, LMP-2B, EBNA-1,   
-2, -3A, -3B, -3C,    -LP, EBERs 
Naive Activate B cell 
 
True latency can be found in peripheral blood B lymphocytes after resolution of primary 
infection. In this state the EBV DNA is circular, packaged with cellular histones, 
replicates only once during mitosis, and is partitioned in the daughter cells (Thompson 
and Kurzrock, 2004). At the opposite end, during latency III the host cell proliferation is 
driven by EBV and all the latency genes are expressed (Werner et al., 2007). 
During primary infection lytic replication occurs in the Waldeyer ring, then the newly 
formed virions infect naïve B cells, inducing the latency III programme (Figure 1.4). 
The activated B lymphoblasts migrate into lymphoid follicles, where they initiate a 
germinal center reaction shifting to the latency II programme that provides the cells with 
signals preventing apoptosis. At this point the infected B lymphocytes return to the 
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blood stream as resting memory B cells, having turned to the latency 0 programme. 
Afterward, whenever they proliferate the latency I programme is activated.  
 
    
Figure 1.4. The different replication programmes used by EBV during primary 
infection. (Young and Rickinson, 2004) 
 
 
The resting memory B lymphocytes are the long term reservoir of the virus when the 
primary infection is terminated. 
In infected cells, EBV circularizes into an episomal form, but integration into the human 
genome may also occur (Morisette and Flamand, 2010). In a cohort of 104 cases of 
EBV-associated diseases integration was demonstrated in 11 cases (Ohshima et al., 
1998). 
 
1.1.2.3. EBV-DEPENDENT B-CELL TRANSFORMATION 
The EBV is able to transform resting B lymphocytes mainly through the coordinate 
action of EBER, latent membrane protein (LMP), and Epstein-Barr nuclear antigen 
 
 10 
(EBNA) molecules. EBERs and EBNA-1 effectively prevent apoptosis (Komano et al., 
1998; Kennedy et al., 2003), in addition LMP1 and LMP2A provide the cell with 
survival signals (Maier et al., 2006; Thorley-Lawson, 2001). Moreover, EBERs induce 
overexpression of IL-10, which has a growth factor-like effect on B lymphocytes 
(Kitagawa et al., 2000). EBNA-2 and EBNA-LP induce shift from G0 to G1 phase via 
activation of Cyclin 2A (Sinclair et al., 1994), whilst EBNA3C supports T cell cycle 
(Maruo et al., 2006). The immortalized lymphoblastoid cells that are generated in vitro 




1.1.3. EBV-ASSOCIATED DISEASES 
Primary infection generally occurs in the oral cavity through infected saliva (Thorley-
Lawson, 2001). The incubation period ranges between 30 and 50 days, and the full-
blown disease may show different degrees of severity. It has been estimated that 95 % of 
adult people worldwide are EBV-positive, in many cases unknowingly since infection is 
in most cases asymptomatic or causes mild, flu-like symptoms. This circumstance 
occurs predominantly in children, whilst people having primary infection during or after 
the second decade more likely develop infectious mononucleosis (IM), also called 
glandular fever in the UK. In individuals with severe immune suppression, primary EBV 
infection may pose a serious threat (Luzuriaga and Sullivan, 2010) and develop into 
fuminant haemophagocyic lymphohistiocytosis with multiorgan failure.  
The EBV can immortalize B lymphocytes in vitro and transform human cell in vivo, due 
to the ability to induce proliferation and to inhibit apoptosis. Not surprisingly, 
expression of EBV antigens is associated with several hematological malignancies, 
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epithelial carcinomas and mesenchymal tumors, that as a whole account for about 1 % 
of the malignancies occurring in humans (Parkin, 2006). 
 
1.1.3.1. CLINICALLY RELEVANT EBV PRIMARY INFECTIONS 
 
1.1.3.1.1. Infectious Mononucleosis 
Usually the presenting symptoms include pharyngitis, malaise, fatigue, fever, 
lymphadenopathy and splenomegaly (Odumade etal., 2011; Hurt and Tammaro, 2007).  
Blood analyses show lymphocytosis with atypical lymphocytes (Figure 1.5). Diagnosis 
is routinely made by heterophile antibody test. 
 
                            
Figure 1.5. Peripheral blood smear of a case of IM, 
showing an atypical lymphocyte. Wright-Giemsa stain      




Hematological complications are frequent but generally mild; severe complications 
occur in about 5 % of the cases and involve splenic rupture, upper airway obstruction 
and neurologic complications. In rare cases primary EBV infection triggers an acquired 
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hemophagocytic lymphohistiocytosis, often lethal over a few weeks. Nevertheless, most 
of the IM patients recover spontaneously in 2-3 months, albeit fatigue may last longer 
(Luzuriaga and Sullivan, 2010). 
 
1.1.3.1.2. Chronic active and fulminant EBV infections 
The term chronic active EBV infection (CAEBV) indicates the persistence of primary 
infection in immunocompetent individuals for at least 6 months, often accompanied by 
life-threatening complications. These include interstitial pneumonia, hepatic failure, 
gastrointestinal perforation, hematophagocytosis, disseminated intravascular 
coagulopathy, pancytopenia (Fox et al., 2011; Cohen et al., 2011; Sonke et al., 2008). 
Serological analysis shows high titers of IgG antibodies against both capsid and early 
antigens (Fox et al., 2011). In the Western hemisphere the major cell targets are B 
lymphocytes, while in the other hemisphere are T lympocytes and NK cells (Fox et al., 
2011). CAEBV is often associated with underlying immunosupression syndromes but is 
rare in itself, and overall mortality ranges between 42 % and 65 % (Cohen et al., 2011; 
Kimura et al., 2003).  
The X-linked lymphoproliferative disease is a rare immune depression syndrome 
characterized by mutations in SH2D1A or XIAP genes (Coffey et al., 19987; Rigaud et 
al., 2006), that code for molecules involved in interactions between B- and T cells, and 
in regulating apoptosis, respectively (Ma et al., 2007; Wilkinson et al., 2004). The 
individuals with X-linked lymphoproliferative disease are highly susceptible to develop 
a fulminant form of primary EBV infection (Purtilo et al., 1974). 
Due to the poor response to therapy in CAEBV and fulminant EBV infection, 
unconventional treatments are sought after and attention has focused on improving the 
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anti-EBV immune response through hematopoietic stem cell transplant (HSCT) or 
adoptive cell immunotherapy (Cohen at al., 2011; Fox et al., 2011). 
 
1.1.3.1.3. EBV reactivation 
Reactivation of EBV infection occurs after allogeneic HSCT or solid organ transplant 
(SOT), and is more frequent after unrelatred transplants and anti-thymocyte globulin or 
anti-lymphocyte globulin treatment (Hornef et al., 1995; Clave et al., 2004). Recipients 
of HSCT from a CB or EBV seronegative donor are at higher risk of EBV reactivation.  
Reactivation is associated with reduction in immunosuppression and onset of post-
transplant EBV-associated lymphomas.  Rituximab, an anti cluster differentiation (CD) 
20 monoclonal antibody (MoAb), used to pre-empt transformation to PTLD, decreases 
but not abrogates the incidence of this complication (Blaes et al., 2010). 
 
1.1.3.2. EBV-ASSOCIATED HEMATOLOGICAL MALIGNANCIES 
 
1.1.3.2.1. Hodgkin lymphoma 
The Hodgkin lymphoma (HL) tissue is characterized by a few malignant Reed-Sternberg 
(RS) cells surrounded by a number of tumor-infiltrating normal cells (Figure 1.6).  
The RS cells belong to the B cell lineage and, having somatic mutations in the V region 
of the immunoglobulin genes, probably originate form germinal centre or post-germinal 
centre B cells (Kapatai and Murray, 2007). However, RS cells do not express functional 
cell surface immunoglobulins, and in the majority of cases they do not express classical 
B-cell markers such as CD19 or CD20. 
 




                        
 
Figure 1.6. A Reed-Sternberg cell, typical of HL, 
surrounded by lymphocytes. Papanicolau stain. 
(Michelow et al, 2012). 
 
 
The HL is divided into two major types: the classical HL, further divided into four 
histological subtypes, nodular sclerosing, lymphocyte rich, mixed cellularity and 
lymphocyte depleted, the latter being very rare and the nodular sclerosing the most 
frequent. The association with EBV expression is related to the type, being high in the 
mixed cellularity, intermediate in nodular sclerosis and rare in lymphocyte rich (Pallesen 
et al., 1991), but also to geographical and socio-economic factors: it is lower in Western 
hemisphere and it is higher in underdeveloped countries, ranging from 50 % of classical 
HL in Germany to 94 % in Peru (Herbst et al., 1992; Chang et al., 1993). The possibility 
that EBV plays a role in the pathogenesis of the classical form of HL is confirmed by the 
fact that the relative risk of developing HL is 2 to 5 times higher in individuals having 
had IM (Gutenshon and Cole, 1980). The EBV-positive RS cells have a latency II 
pattern of expression, expressing EBNA-1, EBER 1 and 2, LMP1 and 2, and the Bam 




1.1.3.2.2. Burkitt lymphoma 
There are three forms of Burkitt lymphoma (BL): the endemic, the sporadic, and the 
human immunodeficiency virus (HIV)-associated form (Table 1.3).  
While the two latter forms are variably associated with EBV expression, EBV is present 
in almost all the cases of endemic BL. High rates of association with EBV are also 
found in some geographical areas, such as Egypt and Brasil, where BL is not endemic 









Although BL is quite uncommon in western countries, the endemic form accounts for 3 
out of 4 malignancies in children in equatorial Africa. Plasmodium falciparum or HIV 
infection increase the risk of developing BL, possibly due to the suppression of the T-
cell immune response induced by these pathogens (God and Haque, 2010). Mortality at 
5 years is related to patient’s age, ranging in the USA from about 25 % in children to 
about 75 % in elderly (Mbulaiteye et al., 2010) 
BL is originated by the translocation of the Myc oncogene into one the V(D)J region of 
immunoglobulin genes on chromosomes 14, 2 or 22. Tumor cells in BL express B cell 
markers such as CD19, CD20 and CD22, and express immunoglobulins at the cell 
surface, generally IgM (Brady et al., 2007; Weils et al., 1982). In general they also show 
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features of germinal centre centroblasts, expressing CD10 and B-cell lymphoma 6 
(BCL6), and having undergone hypermutation (Blum et al., 2004; Chapman et al., 
1998). However, there is evidence of intraclonal heterogeneity, and a possible origin of 
BL also from memory B cells has been suggested (Brady et al., 2007). Diversity is in 
part related to the EBV status: EBV-negative BLs show lower mutation rates and no 
sign of antigen selection (Bellan et al., 2005). In the EBV-positive BL cells, generally 
only the EBNA-1 and the EBER 1 and 2 are expressed (Brady et al., 20076). 
 
1.1.3.2.3. Post-transplant lymphoproliferative disorders 
The term post-transplant lymphoproliferative disorders (PTLD) encompasses several 
lymphomatous diseases, ranging from myeloma to B-cell or T-cell lymphoma, arising in 
patients having received HSCT or SOT. The most common histology seen is that of 
Diffuse Large B-Cell Lymphoma (DLBCL) The onset of the disease is related to 
therapeutic immune suppression. The incidence of PTLD is variable, being about 4 % in 
HSCT and 1.2 % in SOT (Sundin et al., 2006; Dharnidharka et al., 2002).  In the latter 
case the incidence is related to the type of organ transplant, being highest in small bowel 
and in thoracic organ transplantation and lowest in kidney transplantion (Gottshalk et al., 
2005; Trappe et al., 2012).  The frequency of EBV expression in B-cell PTLD is about 
80 %, a little less in T-cell lymphomas (Michelow et al., 2012). The EBV-positive 
PTLD occurs mainly in children, develops earlier, and has a better prognosis than the 
EBV-negative one (Michelow et al., 2012).  
Noteworthy, a study performed on PTLD after HSCT showed that the disease arises 
mainly in patients having received a T-cell depleted preparation or a treatment with anti-
thymocyte immunoglobulins (van Esser et al., 2001). Immune suppressive treatment for 
GVHD is also a major risk factor (Barker et al., 2001). Complete resolution of EBV-
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positive PTLD can be achieved through reduction of the immune suppression (Shaffer et 
al., 2010). Taken together, these data support the concept that PTLD needs a severely 
depressed immune environment in order to emerge. In the United Kingdom, where 
alentuzumab, an anti CD52 MoAb, is commonly used for T cell depletion, PTLD is less 
frequent, probably due to the concomitant eradication of B cells by the drug.   
The timing of emergence of PTLD differs between HSCT and SOT, and this might have 
an impact on a hypothetical adoptive T-cell therapy (ATCT). The median onset of PTLD 
is at day 78 after HSCT (Sundin et al., 2006), i.e. when the patient is still severely 
immune suppressed. Instead, the median onset of PTLD after SOT is 48 months (Evens 
et al., 2010), when patients are on maintenance immunosuppression. Cases occurring 
after 10 years post-SOT account for more than 10 %.  
The pattern of latent gene expression in PTLD is the most extensive, categorised as 
latency III, consisting of EBERs, LMP1 and 2, and all the EBNA proteins (Rickinson 
and Moss, 1997; Michelow et al., 2012), but also some lytic antigens are expressed, 
mainly BZLF1 (Montone et al., 1996; Oertel et al., 2002). More than 50 % of patients 
respond to the anti CD20 MoAb rituximab, however relapse occurs frequently, also due 
to downregulation of CD20 expression by the tumour cells (Moosman et al., 2010). 
 
1.1.3.2.4. Diffuse large B cell lymphoma of the elderly 
The diffuse large B cell lymphoma (DLBCL) of the elderly is a subtype of DLBCL 
occurring in people over 50 years of age and without immunodeficiency or history of 
lymphoma, and is characterized by rapid progression and poor response to therapy. 
Despite the name, a disease with the characteristics of the DLBCL of the elderly can 
also be found in young individuals (Castillo et al., 2016). As it is rare, little is known of 
it. Tumour cells derive from post-germinal centre B cells, express CD19, and frequently 
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also CD20 and CD30. The latency patter is unclear, some claiming that EBV positive 
cells display the latency III type (Castillo et al., 2011), while others suggesting that most 
of the tumours express LMP1 and 1 out of 3 also EBNA-2 (Adam et al., 2011). 
 
1.1.3.2.5. Primary central nervous system lymphoma 
The primary central nervous system lymphoma (PCNSL) is in general associated to HIV 
infection. In these cases the presence of EBV can be detected in 90 % of patients, whilst 
in immunocompetent patients EBV is generally absent (Fine and Mayer, 1003). Tumour 
cells express the B-cell markers CD19, CD20 and CD22. LMP1 and EBER 1 are 
expressed in almost all the EBV-positive PCNSLs, and EBNA-1 only in half of them 
(Guterman et al., 1996). Other studies indicate a broader pattern of latent gene 
expression, particularly in those associated with HIV (Michelow et al., 2012). 
 
1.1.3.2.6. Lymphomatoid granulomatosis 
This is a very rare extranodal lymphoproliferative disease with extensive 
angiodestruction, almost invariably associated with EBV expression. In lymphomatoid 
granulomatosis, EBV-positive tumor cells are of B lineage and have a pattern of latent 
gene expression of type III (Dunleavy et al., 2012).   
 
1.1.3.2.7. Extranodal T- and NK-cell lymphomas 
Although B-cells are the preferential target of EBV, the virus can infect and transform 
also NK cells, NK/T cells and T lymphocytes, either CD4+ or CD8+ ones. Actually, 
EBV is associated with a number of non-B lymphomas, such as immunoblastic T-cell 
lymphoma, cutaneous T-cell lymphoma, aggressive NK cell leukemia/lymphoma and 
nasal NK/T cell lymphoma (Carbone et al., 2008). The latter, like the nasopharyngeal 
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carcinoma, is more common among orientals, in particular Chinese. EBV is present in 
almost all of these tumors (Dunleavy et al., 2012). Tumour cells from extranodal T- and 
NK-cell lymphomas express CD3, CD56, CD2, granzyme B and perforin, but not CD4 
and CD16, and only occasionally CD8 (Michelow et al., 2012; Fox et al., 2011). The 
latency pattern is of either type I or type II, with predominance of the latter type 
(Michelow et al., 2012; Dunleavy et al., 2012; Fox et al., 2011). Interestingly, in this 
disease LMP2 is expressed mainly in a truncated form (Fox et al., 2010). 
 
1.1.3.2.8. Other lymphomas 
EBV expression can occasionally be found in the other lymphoproliferetive diseases.  
In the rare plasmablastic lymphoma, EBV expression was described in cases associated 
with HIV infections (Ferrazzo et al., 2007).  
In the primary effusion lymphoma the association with EBV is variable (Michelow et 
al., 2012); in the positive cases tumor cells express EBNA-1 and low levels of LMP1 
and LMP2 (Horenstein et al., 1997).  
A few cases of secondary B-cell lymphomas have been described in patients with 
angioimmunoblastic T-cell lymphoma. They are EBV-positive large B-cell lymphomas, 
often with extranodal localization, and are supposed to arise as result of the severe 
immune suppression associated with the T-cell lymphoma (Yang et al., 2012; Smeltzer 
et al., 2012). 
 
1.1.3.3. EBV-ASSOCIATED SOLID TUMORS 
 
1.1.3.3.1. Nasopharyngeal carcinoma 
Nasopharyngeal carcinoma (NPC) is a rare tumor in western countries, but is very 
common in south-eastern China, being the 3rd most common cancer in men and, to a 
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lesser extent, among Inuits (Yu and Yuan, 2002). It is an aggressive epithelial carcinoma 
originating from nasopharyngeal mucosa: tumour cells are positive for cytokeratins and 
do not express CD45. Three histological types have been identified: the keratinizing 
squamous cell carcinoma, the non-keratinizing squamous cell carcinoma, and the 
basaloid squamous cell carcinoma. The former type does not express EBV antigens; in 
the other types expression is close to 100 % but is restricted to EBNA-1, LMP2, EBERs 
and BARTs, LMP1 being variably expressed (Michelov et al., 2012; Dawson et al., 
2012). 
The fact that NPC is mainly found amongst Chinese people suggests other aetiological 
factors in addition to EBV. There is some evidence of genetic predisposition; the tumour 
often runs within families and certain human leukocyte antigen (HLA) antigens seem to 
predispose to the disease such as HLA B46. Environmental factors have also been 
blamed, in particular it was observed that the disease is found in regions with high 
consumption of preserved salty fish. Although over 70% of the patients can be cured by 
radiotherapy if they present in early stage, late stage disease and refractory disease have 
poor prognosis. 
 
1.1.3.3.2. Lymphoepithelial-like gastric carcinoma 
This tumour accounts for about 10 % of gastric carcinomas (Chen et al., 2012). As 
compared to gastric adenocarcinoma, the lymphoepithelial-like gastric carcinoma affects 
the upper portion of the stomach, arises in younger patients, has a better prognosis, and 
EBV positivity is much higher, 80 % instead of 16 % (Deyrup, 2008; Delecluse et al., 
2007). EBV-positive gastric carcinomas express EBNA-1, EBERs, BARTs, and in 40 % 
of the cases LMP2A (Iisaza et al., 2012). It is of note that also lytic gene transcripts have 
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been found in EBV-positive gastric cancer samples, albeit immunohistochemistry has 
failed to detect lytic antigens (Tang et al., 2012; Osato and Imai, 1996). 
 
1.1.3.3.3. EBV-associated smooth muscle tumors 
These mesenchymal tumors are quite rare, and are frequently multifocal but metastases 
have not been described, so surgery is the first-line treatment. The pattern of latent gene 
expression is unclear, the cases investigated being a few and the results obtained 
contradictory (Deyrup, 2008). 
 
1.1.3.3.4. Follicular dendritic cell tumor 
The origin of this rare, low-grade tumor generally affecting young people is debated, 
whether hematopoietic or mesenchymal (Deyrup, 2006). Tumor cells express CD21, 
CD35, vimentin and fascin, and show variable expression of CD45. EBV is present in 
30 % of tumors (Michelov et al., 2012). Since LMP1 is a common finding in EBV-
positive cases (Cheuk et al., 2001), the latency should be of type II or III, but further 
studies on larger cohorts are required. 
 
1.1.3.4. OTHER DISEASES POSSIBLY ASSOCIATED WITH EBV 
Whilst the association of EBV with the diseases mentioned above is widely accepted, 
the association with other diseases is controversial. 
EBV DNA has been found with some frequency by the highly sensitive polymerase 
chain reaction (PCR) in breast cancer samples, however the detection of viral gene 
transcripts or proteins has been occasional and has raised a number questions; it seems 
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that EBV infection of mammary cells is rare, and the cells containing the viral genome 
in breast tumour are very few (Huang et al., 2003). 
Some evidences, albeit still inconclusive, have been found for a role of EBV in the 
pathogenesis of systemic lupus erythematosus, multiple sclerosis and myocardial 























1.2. T LYMPHOCYTES 
 
1.2.1. T-CELL DEVELOPMENT AND DIFFERENTIATION 
T cells develop in the foetus from common lymphoid progenitors committed for T cell 
differentiation, which migrate from bone marrow to the thymus. There they undergo 
processes of selection and maturation that lead thymocytes to become mature naïve T 
lymphocytes (TN), which enter the bloodstream. Upon antigen encounter with the 
cognate antigen, TN progressively differentiate into memory T lymphocytes. 
 
1.2.1.1. THYMIC MATURATION 
T-cell precursors entering the thymus do not express most of the markers characteristics 
of mature circulating T lymphocytes, including both CD4 and CD8 molecules 
(Hernandez et al., 2010). These markers will be expressed following the activation of a 
proliferation and differentiation programme triggered by the interaction with thymic 
stromal cells.  The first molecule of the T cell receptor (TCR) complex to be expressed 
by double negative T cells is CD3, afterward the complex process of rearranging the 
TCR genes starts (Murphy et al., 2011). A failure in generating a functional TCR leads 
to cell apoptosis, instead a successful rearrangement of either  and  or  and  genes 
results in generation of  or  T cells, respectively. During the later steps of TCR 
gene rearrangement the  T cells express both the CD4 and CD8 molecules, becoming 
double positive T cells. At this point the surviving thymocytes are selected on the basis 
of their affinity for the self HLA Class I or Class II molecules loaded with self peptides. 
T cells with a TCR that does not recognize self HLA/self peptide complexes undergo 
apoptosis by neglect. T cells expressing a TCR with high avidity for self HLA/self 
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peptide complexes are negatively selected, and in this way the vast majority of 
potentially autoreacting T cells is deleted. Finally, T cells expressing a TCR with weak 
avidity for self HLA/self peptide complexes receive survival signals, for which they are 
positively selected (Hernandetz et al., 2010).  
However, some cells expressing a TCR with high affinity for a self peptide escape 
negative selection and become thymic-derived regulatory T cells (Tregs) (Jordan et al., 
2001). These cells do not proliferate and do not secrete cytokines when challenged with 
the cognate antigen but suppress the proliferation of normal T cells and contribute to the 
maintenance of peripheral tholerance.  
Double positive T cells undergoing positive selection retain the expression of the sole 
CD8 or CD4 molecule, depending on whether their TCR interacts with Class I or Class 
II HLA molecules respectively, becoming single positive, mature T lymphocytes. Due to 
failure in rearranging TCR genes or to inappropriate interaction with self HLA/self 
peptide complexes, 98 % of T cells developing in thymus die off, and only 2 % exit 
thymus as mature T lymphocytes (Murphy et al., 2011). 
In humans the thymus is fully developed at birth and the rate of T lymphocyte 
production remains high up to puberty; afterward the organ shrinks, and production of T 
lymphocyte progressively drops, albeit generation of mature T lymphocytes occurs at 
low rate for the rest of the life (Murphy et al., 2011).  
 
1.2.1.2. THE ROLE OF INTERLEUKIN-7 IN THYMUS 
The orderly sequence of events leading to the generation of mature T lymphocytes is 
orchestrated through cell to cell signals exchanged between T cells and thymic stromal 
cells, and through cytokines present in the extracellular milieu. In this regard a crucial 
role is played by interleukin (IL)-7, secreted by non-hematopoietic thymic epithelial 
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cells (Hong et al., 2012). In particular IL-7 induces proliferation and differentiation of 
both T-cell precursors and double negative T cells (Varas et al., 2009; Yarilin and 
Beliakov, 2004), increases the rearrangement of  and  TCR genes (Okamoto et al., 
2002), and promotes, with IL-15, the specification of CD8+ T lymphocytes (McCaughtry 
et al., 2012). 
 
1.2.2. MATURE T LYMPHOCYTES  
 
Following antigenic stimulation TN start a differentiative programme that results in the 
cells progressively losing their replicative potential while acquiring increasing effector 
functions. 
 
1.2.2.1. NAÏVE T LYMPHOCYTES 
Mature T lymphocytes egressing from the thymus are classified as naïve (TN), in that 
they have not yet encountered the antigen recognized by the TCR they express. TN are 
phenotypically characterized by the co-expression of chemokine receptor (CCR) 7, 
CD45RA and CD62L (Figure 1.7). 
A small percentage in this subset is represented by recent thymic emigrants, young T 
cells which differ from classical TN cells both phenotypically and functionally (Berkley 
et al., 2013).   
TN lymphocytes continuously shuttle between lymphoid tissues via blood and lymphatic 
vessels. In doing so the CD8+ T lymphocytes come in contact with the complexes 
between peptides and HLA Class I molecules expressed by all the nucleated cells, and 
the CD4+ T lymphocytes come in contact with the complexes between peptides and 
HLA Class II molecules expressed by antigen presenting cells (APCs), mainly DCs. The 
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encounter of a TN lymphocyte with the cognate antigen starts a differentiation 
programme that leads the cell to expand clonally and to acquire a different phenotype 
and new functions characteristic of memory T lymphocytes.  
 
 
                          
Figure 1.7. Antigenic stimulations induce progressive differentiation of mature T 
lymphocytes. The differentiative steps are characterized by change in phenotype, 
progressive loss of proliferative potential and increase in effector functions. After 
prolonged antigen stimulations, T lymphocytes become exhausted, non functional and 
eventually die. (Klebanoff et al., 2006) 
 
 
1.2.2.2. MEMORY T LYMPHOCYTES 
1.2.2.2.1. Memory T lymphocyte subsets 
The initial antigenic stimulation leads TN lymphocytes to become central memory T 
(TCM) lymphocytes, lose the CD45RA expression and acquire the expression of the RO 
isoform (Figure 1.8). Following further antigenic stimulation, TCM become effector 
memory T (TEM) and lose the expression of CD62L and CCR7, which targets T 
lymphocyte homing to T-cell areas of lymph nodes, becoming able to infiltrate tissues 
and inflammatory sites (Klebanoff et al., 2006). The final step of differentiation results, 
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after more antigenic stimulation, in TEM lymphocytes becoming CD45RA-positive 
(TEMRA).   
               
 
Figure 1.8. Changes in membrane and intracellular markers associated with CD8+ 
T lymphocyte differentiation. Repeated antigenic stimulation leads CD8+ T 
lymphocytes to shift their phenotype, function and homing characteristics. The response 
profile to some viruses is shown. HCV: hepatitis C virus, Flu: influenza virus, CMV: 
cytomegalovirus. The authors have split TEMRA into two cell subsets on the basis of 





During the differentiation of CD8+ T lymphocytes from TN to TEMRA the different 
subsets progressively lose their capacity to proliferate and secrete IL-2 and acquire the 
ability to release IFN and to exert cytotoxicity, due to the newly acquired ability to 
express perforin and granzymes, and to degranulate. At the same time telomeres undergo 
progressive shortening (Klebanoff et al., 2006; Appay et al., 2008). Other changes in 
phenotype and function take place during CD8+ T-cell differentiation, involving in 
particular membrane proteins regulating cell homing, activation and homeostasis.            
Similar changes occur during differentiation of CD4+ T lymphocytes (Figure 1.9), 
although these phenomena are better known for CD8+ T lymphocytes than for CD4+ 
ones (Appay et al., 2008).  
 
            
 
Figure 1.9. Changes in the expression of membrane and intracellular markers 
associated with CD4+ T lymphocyte differentiation. Repeated antigen 
stimulationleads CD4+ T lymphocytes to modify their phenotype and functions. Perf: 





Altough most of the markers follow the same trend during memory cell differentiation in 
CD4+ and CD8+ T cells, some differ in the two cell subsets, like CD11a. 
It has to be noted that the phenomenon of T lymphocyte differentiation is more a 
continuum than a progression through discontinuous steps, therefore any categorization 
into subsets is a bit factitious.  The most widely used classification is based on the 
expression of two markers, CCR7 and CD45RA, but also other categorizations have 
been proposed, for instance by further dividing the TEMRA subset into CD27
+ and CD27- 
(Appay et al., 2008). 
In the peripheral blood of immune individuals the CD8+ T lymphocytes directed against 
different pathogenic viruses have different subset profiles, the response against latent 
EBV infection involving predominantly the TEM and early TEMRA subsets ((Figure 1.8). 
 
1.2.2.2.2. Memory T cells expressing a naïve phenotype 
Two subsets of phenotypically naïve CD8+ T cells with stem cell features and memory 
traits that have enhanced differentiative and proliferative potential have been recently 
described. 
T-memory stem cells (TSCM) have been proposed to constitute the precursor memory T-
cell pool, which lies between TN and TCM in the differentiation pathway (Gattinoni et al., 
2011).  Despite displaying some phenotypic features in common with TN cells, such as 
co-expression of CD45RA and CCR7, and showing ability of self-renewal, TSCM exhibit 
functional characteristics of antigen-experienced cells. These cells are supposed to 
originate from naïve cells, but upon antigenic stimulation they rapidly expand and 
differentiate into memory subsets (Figure 1.10) but also retain the capacity to self-
renew.  For  these reasons  TSCM are currently regarded  as the best candidates for ATCT 
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(Restifo et al., 2012). They represent a small percentage of circulating TN (Gattinoni et 
al., 2011).   
The recently described memory T cells with naïve phenotype (TMNP) represent a subset 
of antigen-experienced CD8+ T cells with naïve phenotype, high proliferative potential 
and polyfunctional capability (Pulko et al., 2016), but it is unclear how they are related 
to TSCM and how thet are generated. Also these cells might be a powerful tool for ATCT. 
   
 
Figure 1.10. Phenotypic and functional characteristics of the early differentiation 
stages of CD8+ T cells. TSCM represent the first differentiation stage after engagement 
with the cognate antigen, and seem to have the highest anti-tumor effect (Restifo et al 
2012)  
 
1.2.2.2.3. Role of interleukins in T lymphocyte expansion 
The cytokine that plays a major role both in vitro and in vivo in driving proliferation and 
differentiation of T lymphocytes is IL-2 (Murphy et al., 2011). Instead, IL-7 supports the 
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homeostatic expansion of TN outside the thymus. CD8
+ TN lymphocytes activated in the 
presence of IL-7 expand retaining their naïve phenotype (Vieira et al., 1998; Tan et al., 
2001). Moreover, in CD8+ TN lymphocytes, IL-7 without other co-stimuli prevents 
apoptosis and, like IL-15, induces expansion of the cells without loss of their phenotype 
and reduction in telomere length (Wallace et al., 2006). 
 
1.2.2.2.4. T lymphocyte exhaustion 
T-cell exhaustion was initially described in mice during chronic viral infections 
(Gallimore et al., 1998), but the phenomenon was later found to occur also in humans, in 
association with chronic infection with CMV, HIV or hepatitis B or C virus, or with 
cancer, and in elderly people (Fletcher et al., 2005; Wherry, 2011; Baitsch et al., 2011; 
Trzonkowski et al., 2010). Initially, exhaustion can be reverted by removing the 
activating stimulus, but with time it becomes irreversible (Blattman et al., 2009). The 
different functions are lost following a precise sequence. CD8+ T lymphocytes first lose 
the ability to secrete IL-2, to proliferate, and to exert cytotoxicity; afterward the ability 
to secrete tumor necrosis factor (TNF) is lost; lastly the cells become unable to produce 
interferon (IFN)  and to degranulate (Wherry, 2011). Also CD4+ T lymphocytes lose 
their functions sequentially, but the order the functions are lost is less clear. Eventually, 
exhausted T lymphocytes undergo apoptosis.  
Membrane receptors, like PD-1, LAG-3, CTLA-4, and TIM-3 are known to be involved 
in T lymphocyte exhaustion and the transcriptional and epigenetic mechanisms involved 
are being discovered (Pereira et al., 2017). All these molecules are promising targets for 





1.2.3. ANTIGEN PROCESSING AND PRESENTATION 
Protein antigens are not presented to T cells in their native form but are first digested 
into short peptides, and the presentation pathway follows different routes for the 
antigens presented via HLA Class I and those presented via HLA Class II. 
 
     
 
Figure 1.11. The mechanisms of antigen presentation via Class I and Class II. 
Endogenous peptides are generated in the cytosol by proteolytic clivage, transferred into 
the ER where they may be bound by the newly synthesized Class I molecules. 
Exogenous peptides are generated in the phagolysosomes from digestion of endocytosed 






1.2.3.1. ANTIGEN PROCESSING AND PRESENTATION VIA CLASS I 
 
HLA Class I molecules are expressed by all the nucleated cells of the body, and in 
general they participate in monitoring the inner antigens, presenting peptides derived 
from degradation of endogenously synthesized proteins (Figure 1.11). The misfolded or 
denatured proteins, together with part of the newly synthesized ones, are ubiquitinated 
and transported to the proteasome where they undergo enzymatic digestion generating 
both linear and spliced peptides (Vigneron et al., 2017). The resulting peptides ranging 
in length from 8 to 16 residues are then transferred into the endoplasmic reticulum (ER) 
via the coordinated activity of transporter associated with antigen processing (TAP) 1 
and 2 (Neefjes et al, 1993). Associated with these molecules are calreticulin, ERp57 and 
tapasin (Sadasivan et al., 1997; Dong et al., 2009), which mediate the interaction 
between the newly assembled HLA Class I molecules and the translocated peptides that 
display the required characteristics, i.e. generally 9 residues in length and the 
appropriate common motif. Once the peptide is stably bound to the Class I binding 
groove the peptide-loading complex breaks down and the Class I-peptide 
comples is transported to the cell surface. 
DCs can take up exogenous antigens and present them in association with Class I 
(Bevan, 1976), although it is not clear which DC subset exerts cross presentation in 
humans (Joffre et al., 2012).   
The complex Class I-peptide is, with rare exceptions (Bendelac et al., 1994), recognized 






1.2.3.2. ANTIGEN PROCESSING AND PRESENTATION VIA CLASS II 
HLA Class II molecules are expressed by APCs, i.e. DCs, B lymphocytes, macrophages 
and by activated T cells, and they contribute to predominantly monitor the extracellular 
milieu (Figure 1.11). In the ER the newly synthesized Class II molecules are associated 
with the invariant chain (CD74) which partakes to the correct assembling of the complex 
and largely prevents the bindig of peptides by blocking with its distal portion (CLIP) the 
Class II peptide binding site. CD74 also acts as a chaperon, transferring the complex to 
the endocytic pathway, where are also targeted the particles and molecules internalised 
via endocytosis, pinocytosis or autophagy. In the phagolysosome the CD74 molecule is 
degraded by the lysosomal proteases, particularly by cathepsin S (Riese et al., 1996), the 
CLIP peptide and other peptides eventually present in the peptide binding groove are 
uptaken by the non-classical HLA complex DM (Denzin and Cresswell, 1995), and the 
binding site is now free to bind the peptides that are generated by the proteolytic 
machinery, in particular by cathepsins F, L and S (Shi et al., 2000; Hsieh et al., 2002). In 
this case the bound peptides are longer that those bound by Class I, generally ranging 
from 12 to 15 residues in length, although longer peptides can be bound and then 
trimmed afterwards, and the motif requirements are less stringent.  
The complex Class II-peptide is generally recognized by CD4+ T lymphocytes, although 










1.2.3.3. MECHANISMS OF PEPTIDE EDITING AND BINDING TO HLA 
MOLECULES 
The number of peptides that can be generated by digestion of all the potential non-self 
proteins is huge, therefore mechanisms are in place to restrict this number to a size that 
could be managed by the immune system.  
Some mechanisms are operative during processing. It was known for a long time that the 
requirements for clivage by the proteasome enzymes, and those for transport by TAP 
molecules reduce the number of the peptides available in the ER, but more recently it 
has been demonstrated that also tapasin contributes to the peptide editing for Class I. In 
fact, only peptides with high affinity can close the Class I binding groove, nullifying the 
effort of tapasin to keep it open (Fisette et al., 2016). For Class II the number of peptides 
available for binding is mainly determined by the cleavage properties of the lysosome 
enzyme, but it was suggested that also the complexes DM and DO might contribute to 
modulate the repertoire of peptides available for binding (Sloan et al., 1995; van Ham et 
al., 2000). 
Whether a peptide will be bound or not by an HLA molecule depends on the respective 
amino acid sequences. Since in HLA molecules the polymorphic sites are located mainly 
in the peptide binding groove, different HLA molecules have sterically different grooves 
and will bind peptides with different amino acid sequence. It has also to be considered 
that only some amino acid residues in the peptides interact with the HLA molecule, 
while others point to the outside, to be eventually recognized by a TCR. Figure 1.12 





           
Figure 1.12. Scheme of the interactions of the peptide with the TCR and the HLA 
molecules. Some peptides residues anchor the peptide to specific pockets in the HLA 




Generally, a peptide binds to Class I with the residues in position 2 and 9, which 
represent the primary anchor positions and interact with specific pockets, i.e. pocket B 
and F, in the peptide binding groove. Since these pockets differ in the different Class I 
alleles, the peptides bound to a given Class I allele share the same characteristics at the 
anchor positions, that is, display a common motif. For instance, the common motif for 
HLA-A*02:01 is leucine or methionine at position 2 and valine or leucine at position 9. 
The requirements for peptide binding to Class II molecules are less stringent, for 
instance the anchor positions for HLA-DRB1*0101 are 1, 4, 6 and 9, each displaying 
preference for at least six different amino acids. Not surprisingly, Class II molecules 
may display degenerate binding (Southwood et al., 1998). 
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Using experimental data and computational analysis, some alorithms have been created 
which  predict  the  chances  of  a  given  peptide  to  be bound  by a given HLA 
molecule. The fist was SYFPEITHI (Rammensee et al., 1999; http://www.syfpeithi.de/) 
and   several   others  have  followed,   till  the  two  just  published   For Class II    
(Jensen   et  al.,  2018;  http://www.cbs.dtu.dk/services/NetMHCIIpan-3.2/   and 
http://www.cbs.dtu.dk/services/NetMHCII-2.3/). Useful in HSCT and SOT is PIRCHE 
(https://www.pirche.org/pirche/#/), which calculates the permissibility of HLA 
mismatches between recipient and donor by evaluating the relevance of indirect 
recognition  of  the  peptides  resulting  from  the  mismatched  alleles. Others 
algorithms  predict  the  proteasome clivage sites of a protein (http://www.paproc.de/),  





1.2.4. INTERACTIONS BETWEEN CD4+ AND CD8+ T 
LYMPHOCYTES AND PERIPHERAL TOLERANCE 
CD4+ T lymphocytes may occasionally exert cytolytic activity, but in general they role 
is to regulate the innate and the adaptive immune response. The help from CD4+ T cells 
is fundamental in B cell antibody class switching, in enhancing the bactericidal activity 
of phagocytes and, last but not least, in supporting CD8+ T cell function. The latter 
effect is achieved via different mechanisms. By releasing IL-2 CD4+ T cells sustain the 
antigen-driven clonal expansion of CTLs, and this help is provided both for primary and 
secondary response. Moreover, CD4+ T cells are also fundamental in maintaining the 
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memory CD8+ T cells, since the latter cells require continuous exposure to CD4+ T 
cells during the generation of the memory pool after acute infection (Sun et al., 2004). 
The help is provided also via indirect mechanisms. CD4+ T cells via CD40-CD40L 
prime APCs (Schoenberger et al., 1998), which in turn prime the CD8+ T cells, thus 
enabling their expansion and differentiation. Also indirect is the mechanism through 
which CD4+ T helper cells promote migration of CTLs into inflamed tissues, i.e. by 
secreting IFN-γ which induces chemokine secretion in the infected tissues (Nakanishi et 
al., 2009). 
CD4+ and, to some extent, CD8+ T cells can also play a suppressive role on immune 
response. Tregs inhibit T cell function in different ways (Figure 1.13). They can kill T 
cells by direct cytolysis or by inducing apoptosis, also by IL-2 starvation (Ren et al., 
2007; Pandyian et al., 2007), and they can release inhibitory cytokines, namely IL-10, 
IL-35 and TGF. Moreover, Tregs can induce metabolic disruption by releasing 
adenosine or by transferring cyclic AMP into effector T cells (TEff) (Deaglio et al., 
2007; Bopp et al., 2007). In addition, Tregs express CTLA-4, which outcompets the 
molecule CD28 for the binding to CD80 and CD86, therefore depriving activated T 
cells of an important co-stimulus. CTLA-4 engagement of CD80 and CD86 also 
induces in APCs the activation of the potent immune suppressive enzyme 
indoleamine 2,3-dioxygenase (Arce-Silas et al., 2016). 
Although Tregs generally express the CD4 molecule there is also evidence of CD4
-/CD8+ 
T cells with regulatory activity (Rifa’i et al., 2004; Xystrakis et al., 2004; Boor et al., 
2011). 
Tregs are essential for preventing autoimmune responses, limiting chronic inflammatory 




     
Figure 1.13. The mechanisms of Treg-mediated suppression of TEff function.  Treg 
cells suppress T cell function by direct killing, by releasing immune suppressive 
cytokines, by interfering with TEff metabolism and by inducing DCs to switch to a 
suppressive phenotype. (Vignali et al., 2008) 
 
 
Despite the fact that most of the self-reactve T cells are negatively selected in the 
thymus, some escape this selection, due to inadequate presentation in the thymus of 
tissue-restricted antigens, or to cross reactivity of TCRs having passed the thymic 
selection. These cells, which pose the threat of autoimmune diseases, will undergo 
deletion or suppression in periphery. DCs control the balance between TEff and Treg cells 
and are therefore the major actors in maintaining peripheral tolerance. This effect is 
achieved through different mechanisms. Immature DCs constitutively cross present 
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tissue-specific antigens via Class I and this results in deletion or inactivation of the 
responding CD8+ T cells (Luckashenak et al., 2008). The same activity is also displayed 
by lymph node stromal cells (Lee et al., 2007). Moreover, DCs can both expand the Tregs 
derived from the thymus and induce the conversion into Tregs of recently activated 
autoreactive TN cells (Yogev et al., 2012). The circulating Tregs, either of thymic origin 




















1.3. IMMUNE RESPONSE TO EBV 
 
 
1.3.1.  IMMUNE RESPONSE TO EBV IN PRIMARY 
INFECTION 
In healthy individuals primary EBV infection is controlled mainly via T and B 
lymphocytes. During the acute phase, a cytolytic response mediated by CD8+ T 
lymphocytes is mounted predominantly against the lytic antigens BZLF1, BMLF1, 
BMRF1, and BHRF1 (Rickinson and Moss, 1997; Oumade et al., 2011).  Moreover, 
antibodies directed against capsid proteins and some early antigens appear early during 
infection (Linde, 1996; Oumade et al., 2011). This response leads to the clearance of the 
EBV-infected B cells in peripheral blood, which drop from 10 % during the acute phase 
to 1 out of 106 cells during convalescence. 
Latent EBV infection is controlled mainly via cytolytic T-cell response: the EBV 
specific CD8+ T lymphocytes directed against EBNA-3A, EBNA-3B and EBNA-3C 
epitopes are the most frequent (Tan et al., 1999), although more than 50 epitopes, either 
restricted to HLA Class I or Class II molecules, have been identified so far (Hislop et al., 
2007).   
A role in controlling EBV infection has been suggested also for CD4+ T lymphocytes, 
since one out of three cells recognizing EBV-positive lymphoblastoid cell lines (LCLs) 
belongs to this cell subset (Bhaduri-McIntosh et al., 2008). It has been demonstrated that 
EBV-infected cells can effectively be lysed by cytolytic CD4+ T lymphocytes; these 
cells, as compared to their CD8+ counterpart, show a broader recognition of epitopes 
derived from lytic antigens (Long et al., 2011). Most importantly, CD4+ T lymphocytes 
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can also provide help, therefore improving the CD8-mediated CTL activity, as 
demonstrated in vitro by analyzing the immune response to CMV (Hammoud et al., 
2013). Finally, CD4+ T lymphocytes can enhance the anti-viral response through 
mechanisms that are independent of helper or cytotoxic activity: they activate the APCs 




1.3.2. EBV-DEPENDENT IMMUNE ESCAPE 
The immune response to EBV is effective in controlling the primary EBV infection and 
in general in clearing the virus in the lytic phase, but is less effective in destroying the 
virus in the latent phase, being hampered by the several immune escape mechanisms that 
EBV puts in action at this stage.  
The main escape mechanism is based on the fact that the restricted gene expression 
profile during latency reduces the number of antigens potentially detectable by the 
immune system. Moreover, EBV deeply affects the mechanisms of antigen presentation 
via HLA Class I and Class II molecules. EBNA-1 contains a Gly/Ala repeat that affects 
proteasome function, reducing the number of EBNA-1-derived epitopes that can be 
presented via HLA Class I molecules (God and Haque, 2010). The mechanisms of EBV 
evasion of presentation via HLA Class II molecules are still unclear, but they seem to be 
related more to functional impairment of antigen presentation than to reduced levels of 
Class II expression. In this regard the EBV protein BZLF2 seems to interfere with the 
TCR binding at the cell surface level (Ressing et al., 2005). Furthermore, it was found 
that EBV-positive tumor cell lines express much more Class II associated invariant-
chain peptide (CLIP) at the cell surface than EBV-negative cell lines of the same 
histotype, possibly affecting TCR binding (God and Haque, 2010).  
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In addition, the viral late gene product BCRF1, the analogous of the human IL-10, exerts 
a strong immune suppressive activity.  It inhibits the antigen presenting activity of 
monocytes and macrophages (Salek-Ardakani et al., 2002), and inhibits the expression 
of TAP-1 (Rowe and Zou, 2010). TAP activity is also inhibited by BNFL2 that binds to 
the TAP complex and prevents peptide translocation (Rowe and Zou, 2010). 
In EBV-positive BL an effective immune response is also hampered by the fact that 
tumor cells express low levels of the costimulatory molecules CD80 and CD86 (God 
and Haque, 2010). In HL, instead, EBV infection increases through LMP1 the 
expression of PDL-1, the ligand of the immune checkpoint PD-1 (Green et al., 2012). 
PDL-1 is also expressed by more than70 % of PTLD. 
 
 
1.3.3. T-CELL RESPONSE IN EBV-ASSOCIATED 
TUMORS 
The EBV-associated malignancies can be divided on the basis of the patient’s immune 
response potential into two groups: those arising in immune competent patients, such as 
HL or NPC, and those arising in immune depressed patients, such as PTLD or the EBV-
associated malignancies occurring in HIV-positive individuals. 
There is convincing evidence that, despite the numerous mechanisms put in action by 
the EBV to escape or suppress the immune response, recognition of EBV antigens takes 
place in EBV-associated malignancies occurring in immunocompetent patients. The 
level of cell membrane HLA Class I expression and the number of activated CD8+ T 
lymphocytes in peripheral blood is higher in EBV-positive cases of HL than in EBV-
negative ones (Murray et al., 1998; Oudejans et al., 1997). Moreover, circulating EBV-
specific cytotoxic T lymphocytes (CTLs) can be found in HL patients, and HL cells can 
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be lysed by EBV-specific CTLs in vitro (Tsang and Muntz, 2011; Lee et al., 1998). 
Accumulating evidence indicates that also CD4+ T lymphocytes might play a role in the 
immune response to EBV-associated malignancies. Indeed it has been demonstrated that 
CD4+ T lymphocytes specific for EBNA-1 can recognize BL cells in vitro and prevent 
EBV-associated tumor growth in a mouse model (Voo et al., 2002; Fu et al., 2004). 
Despite this evidence the EBV-specific immune response never reaches a level 
sufficient to completely destroy the tumor. 
Instead, in the EBV-associated malignancies arising in immune suppressed patients the 
immune system is constitutively unable to mount an efficient response, although these 
tumors are potentially more immunogenic that those arising in immune competent 
patients. Each of the different EBV-associated human tumor has a peculiar pattern of 
latency gene expression (Table 1.4), and the tumors arising in immune depressed 





Table 1.4. Latency patterns in the most common EBV-associated malignancies. 
(Modified from Thompson and Kurzrock, 2004) 
 
Latency I    Burkitt lymphoma 
     Gastric carcinoma 
 
Latency II    Hodgkin lymphoma 
     Nasopharyngeal carcinoma 
     Extranodal T/NK lymphoma 
 
Latency III    PTLD 




One might speculate that these tumours do not occur in immune competent individuals 
because an intact immune system is able to erase this type of neoplastic cells. In this 
regard a study on 150 EBV-positive patients receiving either unmanipulated or T-cell 
depleted HSCT showed that only the latter developed PTLD (van Esser et al., 2001). On 
this basis, patients with PTLD or HIV-associated EBV-positive lymphomas might get 
advantage of ATCT more than those with EBV-associated tumours arising in immune 
competent individuals. Moreover, the former tumours have the broadest pattern of EBV 
antigen expression, therefore providing a better target for CTL activity. However, some 
degree of immune alteration can also be observed in the latter tumors, either being 






























1.4. T-CELL IMMUNOTHERAPY IN EBV 
ASSOCIATED MALIGNANCIES 
 
Several attempts to treat EBV-associated malignancies with ATCT have been 
performed. Beside a pilot study in 2001 (Chua et al., 2001), five trials have been carried 
out in NPC (Straathof et al., 2005; Comoli et al., 2005; Louis et al., 2010; Chia et al., 
2014; Smith et al., 2016) and all showed that the treatment had no significant short or 
long term toxicity while inducing partial or complete remission roughly in half of the 
patients. In particular the most recent trials showed that ATCT resulted on average in 18 
months progression-free survival in patients with no or minimal residual disease, and in 
a prolonged survival in patients with refractory locally advanced or metastatic disease. 
Encouraging results have also been obtained in trials carried out in HL, where 4 
complete remissions were obtained out of 20 cases refractory to conventional therapy 
(Roskrow et al., 1998; Straathof et al., 2003; Bollard et al., 2004; Lucas et al., 2004). 
However, the most encouraging trials so far have been performed on PTLD. 
 
 
1.4.1. EFFICACY OF ATCT IN PTLD 
PTLD can arise in patients having received HSCT or SOT, and EBV-specific T-cell 
immunotherapy has been conducted in both cases, with slightly different, but 




1.4.1.1. PTLD AFTER HSCT 
The first observation that PTLD arising after HSCT can be treated by donor lymphocyte 
infusion (DLI) dates back to more than 20 years ago (Papadopulos et al., 1994), but the 
use of DLI in this setting has been hampered by the risk of inducing severe GVHD. 
Indeed in a cohort of 27 HSCT patients, mainly pediatric ones, that in most cases 
received lymphocyte infusion for PTLD from HLA-matched donors, 5 developed acute 
GVHD (Dubrovina et al., 2012).  To circumvent this risk, starting from 1995 (Rooney et 
al., 1995), EBV-specific CTLs have been used, generally with good results, albeit most 
of the trials were carried out on a limited set of patients in non-randomised single arm 
studies. Focusing on the ones with the largest cohorts, in a study on 13 patients with 
EBV-positive PTLD, 11 achieved complete remission (Shaffer et al., 2010). In another 
trial complete remission was achieved by 7 out of 10 patients (Icheva et al., 2013). In a 
third study 3 out of 6 patients achieved complete remission (Moosman et al., 2010). 
Finally, in a cohort of 17 patients, 12 achieved complete remission, including 5 patients 
that failed to respond to conventional therapy; noteworthy, those that did not respond 
showed an impaired recognition of tumor antigens in vitro (Doubrovina et al., 2012).  
EBV-specific ATCT has also been used as a pre-emptive approach to prevent PTLD. In 
this case a retrospective analysis showed that none of the 101 HSCT recipients receiving 
EBV-specific CTLs developed PTLD, whilst in the group of 47 patients that received no 
prophylaxis 5 developed PTLD (Heslop et al., 2010).  






1.4.1.2. PTLD AFTER SOT 
The largest trial assessing the effect of adoptive T-cell therapy on PTLD after SOT 
involved 32 patients refractory to conventional treatment that received in vitro expanded 
EBV-specific CTLs from their donors; complete remission was achieved in 14 cases 
(Haque et al., 2007). Better response seemed to correlate with higher percentages of 
CD4+ T lymphocytes in the infused cells and with their longer in vivo persistence. It has 
been suggested that the reduced effectiveness of EBV-specific ATCT in PTLD arising 
after SOT might be related to a shorter in vivo persistence of the infused CTLs, possibly 
related to a better alloreactive response of SOT patients, compared to HSCT ones 
(Shaffer et al., 2010). In this regard a trial was conducted, infusing autologous, in vitro 
expanded CTLs for either prophylaxis or treatment, and it was found that the survival in 




1.4.2. EBV ANTIGENS TO BE TARGETED FOR T-CELL 
ATCT IN PTLD 
So far, most of the peptides used to induce a CTL response for ATCT were derived from 
latent proteins, since PTLD expresses the latency III antigens, i.e. EBERs, LMP1 and 2, 
and all the EBNA proteins (Rickinson and Moss, 1997; Michelow et al., 2012), In a 
study assessing the specificity of immune response in one case of PTLD treated with 
CTLs stimulated with autologous LCLs, the main response was directed against EBNA3 
(Gottschalk et al., 2001); interestingly, when the lymphoma relapsed, the EBNA3 gene 
was found to have mutated. 
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It is widely assumed that, as in other EBV-associated tumors, lytic antigens are not 
expressed in PTLD, despite several evidences indicating that these antigens might be 
expressed as well. Expression of lytic antigens, predominantly BZLF1, was found by 
immunohystochemistry in PTLD specimens (Montone et al., 1996; Oertel et al., 2002). 
In other studies transcripts of lytic antigens were found in high percentages of PTLD 
cases (Hopwood et al., 2002; Porcu et al., 2002). Most importantly, CTL recognition of 
lytic antigens seems to correlate with response to conventional therapy (Porcu et al., 
2002). On these bases, lytic antigens should be included as targets for EBV-specific 
ATCT in PTLD. Evidence is also emerging that, besides CD8+, CD4+ T lymphocytes are 
also important for effective ATCT.  Indeed, cytolytic CD4+ T cell lines specific for lytic 
epitopes effectively lyse LCL cells in vitro (Long et al., 2011). The Class II-restricted 
antigenic repertoire for these epitopes is broader than the Class I-restricted repertoire. It 
was also found that EBNA-1-specific CD4+ T lymphocytes expanded in vivo after 
infusion of poly-specific EBV CTL into PTLD patients (Icheva et al., 2013). Moreover, 
a better response to T-cell immunotherapy in PTLD seems to be related to a higher 
number of EBV-specific CD4+ T lymphocytes in the infused sample (Haque et al., 
2007). These data support the using of CD4+ T lymphocytes to target Class II epitopes 
for EBV-specific T-cell immunotherapy. 
 
 
1.4.3. THE DIFFERENT STRATEGIES FOR OBTAINING 
EBV-SPECIFIC T LYMPHOCYTES  
In order to obtain antigen-specific T lymphocytes one may follow different strategies 
and employ different techniques, each of them having pros and cons. Early studies used 
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in vitro expansion methods, but technological advances have led to using Ag-specific T 
lymphocytes isolated ex vivo, or T lymphocytes transduced with specific TCR genes. 
 
1.4.3.1. IN VITRO EXPANSION OF ANTIGEN-SPECIFIC T LYMPHOCYTES 
EBV-specific T cell lines are usually generated by repeatedly stimulating T lymphocytes 
with autologous, EBV-transformed B LCL cells in the presence of IL-2. In one study, 39  
HSCT patients considered at risk of PTLD received prophylaxis with in vitro expanded 
EBV-specific T cells and none developed lymphoma (Rooney et al., 1998). In vivo 
monitoring post-cell infusion showed a sharp drop in EBV DNA levels in circulating 
peripheral blood mononuclear cells (PBMC). In the same study 2 additional patients that 
developed overt PTLD were also treated with in vitro expanded EBV-specific T cells 
and both experienced a completed and sustained remission.  
The advantage of this approach is that a large number of EBV-specific T lymphocytes 
can be generated, and eventually administered in repeated infusions. On the other hand a 
severe drawback of this approach is the long time it takes to reach a number of antigen-
specific T lymphocytes sufficient for infusion: up to 4 months (Shaffer et al., 2010; 
Bollard, 2013). This length of time might be too much when the disease is in a phase of 
rapid progression, and even when it is not, the delay in treating the patient might affect 
the outcome. Nucleofection of DCs with immunodominant viral antigens has been 
proposed as an effective strategy for reducing the production time of viral-specific CTL 
lines (Gerdemann et al., 2009). Alternatively, the establishment of a bank of allogeneic, 
EBV-specific CTL lines to be used “off the shelf” might overcome the time limitation 
(Shaffer et al., 2010). A small bank with these characteristics has been established by the 
Scottish Blood and Transplant Service (Vickers et al., 2014).  
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However, it is worth mentioning that, when LCL cells are used as stimulators, the 
coverage of latent antigens is incomplete, the response to lytic antigens is missing, and 
there is the risk of the presence of free virus in the preparation (Eiz-Vesper et al., 2012). 
Another problem is related to the fact that, by using LCL cells as stimulators, most of 
the resulting CTLs are directed against EBNA3 and to a lesser extent to LMP2 but only 
minimally against the other latent antigens (Bollard, 2013). The use of DCs loaded with 
peptides derived from the different EBV antigens as APCs might overcome this 
problem. 
Last but not least, the repeated stimulations that lymphocytes undergo during in vitro 
expansion induce the cells to express a late differentiation phenotype, and become easily 
prone to cell exhaustion (Klebanoff et al., 2005; Berger et al., 2008; Baitsch et al., 
2011). 
 
1.4.3.2. ISOLATION OF ANTIGEN-SPECIFIC T LYMPHOCYTES 
Two methods are available for the ex vivo isolation of antigen-specific T lymphocytes 
from PBMC at clinical grade level: both were set up for selecting CTLs recognizing 
CMV, and both are based on immunomagnetic selection, but one uses HLA-multimers 
for selection (Cobbold et al., 2005), while the other selects for IFN-secreting cells 
(Rauser et al., 2004) using cytokine capture antibodies. Both these techniques have been 
used to isolate EBV-specific T lymphocytes (Weisner et al., 2005; Mackinnon et al., 
2008). HLA-multimer selection was used in one case of PTLD, resulting in complete 
remission (Uhlin et al., 2010). IFN capture was used in two small trials on PTLD, 
achieving in both trials a 50 % of complete remissions (Moosman et al., 2010; Icheva et 
al., 2012). PBMC from the HSCT donor were incubated with a pool of EBV-derived 
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peptides, the activated, IFN-secreting cells isolated, and then infused into the recipient 




Figure 1.14. Schematic representation of the method for rapid isolation of EBV-
specific T lymphocytes for ATCT. PBMC are stimulated overnight with EBV-derived 
peptides, then the EBV-specific T lymphocytes are immunomagnetically selected using 




The 3 patients with advanced disease did not respond, but the others experienced a 
complete and sustained remission, accompanied by a significant increase in the number 
of circulating EBV-specific CD8+ T lymphocytes. The great advantage of these 
approaches resides in two facts: the infused cells are minimally manipulated, and the 
whole procedure takes less than two days to perform. 
The purity of antigen-specific T lymphocytes seems to be reduced following 
IFNcapture as compared to multimer-based selection (Eiz-Vesper et al., 2013), but it 
has to be said that in the trials using the former technique no increase in GVHD was 
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detected (Feuchtinger et al., 2006; Moosman et al., 2010; Peggs et al, 2011; Icheva et al., 
2012). On the other hand, only a limited, although expanding, set of Class II multimers 
is currently available, restricting the effectiveness of this technique for the selection of 
CD4+ T lymphocytes. Instead, a number of clinical grade EBV peptides is currently 
available, and pools from LMP-2A, EBNA-1, and BZLF-1 have been used for the 
selection by IFNcapture of both CD4+ and CD8+ T lymphocytes (Eiz-Vesper et al., 
2012).  
To improve the efficacy of this approach the creation of a registry of suitable T 
lymphocytes donors, HLA typed, and with high numbers of EBV-specific T cells could 
be useful for those cases where  a third party donor is the only option. 
 
1.4.3.3. GENE TRANSDUCTION OF T LYMPHOCYTES 
T lymphocytes can be effectively transduced with genes coding for chimeric antigen 
receptors (CARs) or for antigen-specific TCRs (Pule et al., 2008; Hinrichs et al., 2011).  
The major advantage of this technique relies on the fact that autologous cells can be 
used. In case of CAR transduction there is the possibility of off-target toxicity.  
In transduction of exogenous TCR gene, mispairing of  and  chains, leading to 
creation of new TCR specificity can occur, albeit no evidence of alloreactive response 
have so far been detected in humans. A more relevant risk is related to the ability of the 
viral vectors, usually adenovirus and more recently lentivirus, to integrate into the cell 
genome. Indeed, insertional mutagenesis resulted in oncogene activation in 5 cases out 
of 19 in a trial of gene therapy for X-linked severe combined immune deficiency, and 
induced genome instability in 2 cases of chronic granulomatous disease treated with 
gene therapy (Hacein-Bey-Abina et al., 2008; Stein et al., 2010). However, this 
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complication has only been observed in gene therapy of haemopoietic stem cells and not 
in mature lymphocytes. Nevertheless, this has led gene transduction-based ATCT to 
undergo a severe scrutiny. A recent phase I trial on fourteen patients with metastatic 
cancer however showed no side effects for this treatment and suggested its efficacy in 
some cases (Yong-Chen et al., 2016).  
 
 
1.4.4. AUTOLOGOUS VS. ALLOGENEIC SOURCE OF T 
LYMPHOCYTES FOR ATCT 
 
In order to minimize the risk of alloreactive response, the ideal source of T lymphocytes 
for immunotherapy is the patient himself, and this is the case for the gene transduction 
approach. However, in some instances this option is not feasible. This is the case in 
EBV-negative patients, a frequent occurrence in children; but it is also the case of 
elderly people, that have a reduced T-cell repertoire and mount a less effective immune 
response. Moreover, most of the patients at the time of ATCT have received a 
myeloablative treatment, as is the case of HSCT patients, are under immune suppressive 
therapy, as is the case of SOT patients, or have received massive chemo- and/or 
radiotherapy, as is the case of tumor patients, all conditions that severely reduce the 
number and impair the function of their T lymphocytes. 
In the case of HSCT or SOT from living donor, the donor is the source of EBV-specific 
T lymphocytes. Indeed most of the trials conducted so far have used  HLA matched 
allogeneic HSCT donors as source of T lymphocytes. However, there is evidence that 
granulocyte colony-stimulating factor (GCSF) might affect functional activity of T 
lymphocytes by polarizing them to a Th2 profile, suggesting that GCSF-treated HSCT 
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donors might not be the best source of T lymphocytes for immunotherapy early after 
HSCT; in these cases a third party donor should be considered (Franzke et al., 2003; Toh 
et al., 2009).  
A third party is required when the donor is EBV-negative, or is not available, as in the 
case of SOT from cadaveric donors or HSCT from umbilical cord blood (CB), or in 
patients with EBV-associated solid tumors. In a trial with 10 patients with severe viral 
infection, ATCT with T lymphocytes selected with multimers from third party donors 
was performed with encouraging results (Uhlin et al., 2012). In another study, two 
patients with PTLD after HSCT receiving in vitro expanded EBV-specific CTLs from 
third party donors showed complete remission (Barker et al., 2010). Another trial, 
including third party donors, confirmed the efficacy of this approach (Doubrovina et al., 
2012). 
 
1.4.4.1. THE POSSIBILITY OF GVHD AFTER INFUSION OF ALLOGENEIC T 
LYMPHOCYTES 
A life-threatening complication of infusing CTLs from HLA-mismatched donors might 
be represented by severe GVHD, however evidence from literature suggests that this 
risk is possibly overestimated. Indeed, in a study on 101 HSCT recipients receiving 
EBV-specific CTLs as prophylaxis for PTLD no increase in GVHD was found, nor de 
novo GVHD episodes were detected after CTL infusion (Heslop et al., 2010). Also in a 
retrospective analysis on 73 HSCT patients receiving T-cell ATCT for EBV alone or in 
combination with CMV and/or adenovirus from HLA mismatched donors, no increase in 
acute or chronic GVHD was detected, as compared to patients receiving CTLs from 
HLA-matched donors (Melenhorst et al., 2010). In a cohort of 44 patients, 17 treated 
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with EBV-specific T cells and 27 with DLI, GVHD was observed only in the latter 
group (Doubrovina et al., 20120). 
As it regards SOT, in a study involving 32 patients, neither GVHD nor any other 
adverse affect were observed (Haque et al., 2007).  
 
 
1.4.5. THE IMPORTANCE OF T-CELL SUBSETS IN ATCT 
The ability of transfused antigen-specific T lymphocytes to survive and expand into the 
host is crucial for the outcome of ATCT: only a significant clonal expansion can induce 
an effective immune response in vivo.  The fact that clinical response to ATCT is related 
to the long term in vivo persistence of transfused cells was first observed in trials on 
melanoma patients (Yee et al., 2002). As discussed above, the ability to expand is 
progressively lost during differentiation, from TN to TEMRA. It was demonstrated in 
primates that in contrast to TCM, TEM lymphocytes albeit endowed with proliferative 
potential in vitro fail to replicate in vivo (Berger et al., 2008). Moreover, it has been 
recently found that antigen experienced T cells promote via Fas-mediated cell-to-cell 
contact the differentiation of TN and the rapid loss of the less differentiated T-cell 
subsets (Klebanoff et al., 2016) In a mouse model of adoptive T cell therapy, this 
phenomenon resulted in an increased in vivo persistence of the transfused cells and an 
improved survival of the mice receiving purified TN cells, compared with mice infused 
with unfractionated T cells  (Klebanoff et al., 2016). Notwithstanding this, in most of the 
cases unfractionated T lymphocytes are used for ATCT. 
Another cause of failure of ATCT is related to the rapid exhaustion of transfused cells. It 
was demonstrated in melanoma patients that infused T lymphocytes infiltrating 
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metastases showed signs of exhaustion (Baitsch et al., 2011). In addition, it was found 
that clinical responses and in vivo persistence of infused T lymphocytes were related to 
longer telomeres (Zhou et al., 2005), a marker of less differentiated memory T-cell 
subsets.  
These findings indicate that TEM lymphocytes may be poor candidates for T-cell ATCT: 
although they are endowed with better effector functions, they have less proliferative 
potential than TCM lymphocytes and are more prone to cell exhaustion.  Indeed, TCM 
lymphocytes are considered by some the best cells for infusion (Klebanoff et al., 2005; 
Hinrichs et al., 2011). This has to be taken into consideration in the choice of strategy 
for ATCT. Whereas the in vitro expansion results, due to repeated and prolonged 
stimulation, in generation of highly differentiated T lymphocytes, gene transduction or 
ex vivo antigen-specific cell selection result in minimal changes to T lymphocyte 
differentiation. 
 
1.4.5.1. T LYMPOCYTES FROM UMBILICAL CORD BLOOD IN ATCT 
CB is widely used for HSCT, but its use as source of T lymphocytes for ATCT has been 
scarcely investigated, despite evidence suggests that T lymphocytes from CB display a 
normal response to tumor antigens but a reduced one to alloantigens (Merindol et al., 
2010).  Functionally active CTL lines that react to CMV, EBV and adenovirus have 
been produced by in vitro expansion from CB (Micklethwaite et al., 2010). Moreover, a 
pilot trial using CB as source of T lymphocytes on two case of PTLD refractory to 
conventional therapy resulted in both the patients achieving a sustained complete 




1.5. AIMS OF THE STUDY 
 
 Based on the considerations put forward in paragraph 1.4, it is evident that ATCT, 
albeit promising, is still in its infancy, and needs to be ameliorated in order to become a 
first or a second line treatment for human diseases. In particular there is the necessity to 
improve the performance of ATCT for those cases where a third party donor of EBV-
specific lymphocytes is the only available possibility. Therefore, focus has been put on 
three areas that in our opinion deserved to be further investigated. 
 
1.5.1. THE SET UP OF A REGISTRY OF THIRD PARTY 
DONORS 
So far, the frequency of EBV-specific T lymphocytes in the blood of third party donors 
used for ATCT trials has not been checked. However, the in vitro expansion of EBV-
specific T cells is a time-consuming procedure, requiring 3-4 weeks for the cells to reach 
an adequate number, and 1 or 2 for the quality controls. This length of time does not fit 
well with the treatment of rapidly progressing diseases, such as PTLD. So we have 
aimed at creating a panel of HLA-typed healthy volunteers with high levels of 
circulating EBV-specific T lymphocytes. In this way, it would be possible to provide at 
short notice fresh T lymphocytes for effective ex vivo selection or in vitro expansion of 
EBV-specific T cells. Moreover, the registry could benefit pediatric transplant patients 
at high risk of donor-derived EBV reactivation; in this case the EBV-negative donors 




1.5.2. THE STUDY OF PHENOTYPICALLY NAÏVE 
MEMORY T CELLS. 
The two T-cell types with naïve-like phenotype and memory traits, TSCM and TMNP, are 
currently ranked among the best candidates for ATCT (Restifo et al., 2012; Pulko et al., 
2016), however al lot still needs to be done in order to fully understand their origin and 
function. 
Despite sharing several phenotypic and functional characteristics, TSCM and TMNP differ 
in their extended phenotype, particularly in the expression of CD95 (Pulko et al., 2016), 
and it is not clear whether they represent different stable T-cell subsets or are the same 
cells transiently exhibiting different membrane markers, as expression of their plasticity. 
Moreover, the mechanisms leading to the generation of these cell subsets still need to be 
fully elucidated. Although CD8+ TSCM can be produced in vitro by activating TN cells 
with IL-7, IL-21, and the glycogen synthase-3β inhibitor TWS119 (Sabatino et al., 
2016), the physiological mechanisms generating these cells are unknown. As for TMNP, 
nothing is known about their origin. 
Therefore, we have aimed at elucidating the relationship between these two T-cell 
subsets, and to investigate how they are generated.  
 
1.5.3. THE STUDY OF CB-DERIVED CD8+ T 
LYMPHOCYTES AS SOURCE OF CELLS FOR TCR 
GENE TRANSDUCTION 
An important prerequisite to move T-cell immunotherapy from promising pilot trials to 
established therapy consists in improving the in vivo performance of the infused T cells. 
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As shown in paragraph 1.4.5, the less differentiated are the infused cells and the longer 
is the in vivo survival, a correlate of therapeutic efficacy.  
This makes T lymphocytes from adult donors, being predominantly memory cells, not 
the best candidates for T-cell immunotherapy. After the activation that is required to 
perform gene transduction, and the several rounds of activation necessary for in vitro 
expansion, these cells become more differentiated and senescent. The further activation 
they undergo in vivo after infusion likely induces a shift toward terminally differentiated 
subsets, and eventually results in exhaustion and cell death. Ideally, the best candidate 
should be TN cells, which have the greatest proliferative and differentiative potential. 
However, gene transduction for ATCT has been carried out so far on blood lymphocytes 
from adults, which are predominantly memory cells. Since T lymphocytes from CB are 
mostly TN (Beck and Lam-Po-Tang, 1994), our aim was to determine whether CB 
provides a better source of T cells for TCR engineering, in comparison to peripheral 
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Early phase clinical trials have demonstrated that ATCT with autologous cells is 
effective and safe in Epstein-Barr virus (EBV)-associated malignancies refractory to 
conventional therapy. Similar outcome and safety was also achieved using EBV-specific 
CTL generated from third party donors for treatment of both HSCT- and SOT-associated 
PTLD. However, to move from early proof-of-principle trials to established practice, it 
is important to establish a registry of HLA-typed, third party T-cell donors with high 
levels of circulating EBV-specific T lymphocytes so that donors can be recruited at short 
notice to donate PBMC for CTL generation. We have selected 17 HLA Class I restricted 
and 12 Class II-restricted EBV peptides derived from both lytic and latent antigens, and 
used them to activate T lymphocytes from 108 HLA-typed platelet donors expressing 
the Class I and Class II alleles that are most common in the UK, covering greater than 
90% of the population. Screening was performed using interferon (IFN) Elispot, as 
preliminary experiments demonstrated it to be more sensitive and suitable than 
intracellular IFN staining or HLA-multimer staining. We found a remarkable inter- and 
intra-donor variability in the magnitude of the response to the different peptides, but 
strong responses were found for peptides derived from both latent and lytic antigens, and 
for both Class I- and Class II-restricted peptides. For the latter peptides, there was 
evidence of promiscuous response. For each donor we were able to define the pattern of 
response to the peptides restricted to the donor’s haplotypes, identifying for each allele 
at least one high-responding donor. Our results support the feasibility of setting up a 






About 1% of human tumours are associated with the expression of Epstein-Barr virus 
(EBV) antigens:  almost all the endemic forms of Burkitt lymphoma (BL), from 50 to 90 
% of Hodgkin lymphoma (HL), more than 90 % of nasopharyngeal carcinoma (NPC), 
and about 80 % of post transplant lymphoproliferative disorders (PTLD) express various 
patterns of EBV antigens (1-4). This makes EBV-positive tumours suitable targets for 
EBV-specific cytotoxic T lymphocytes (CTL). Indeed, several trials have been 
conducted to assess safety and efficacy of ATCT in EBV-associated malignancies. 
Although limited results have been obtained in HL (5-8), the results obtained in other 
tumor types are encouraging. The three trials for NPC (9-11) showed that the treatment 
had no significant toxicity whilst inducing complete remission in more than half of the 
patients. The same conclusions can be drawn for PTLD, the EBV disease expressing the 
broadest set of viral antigens. The largest trial for PTLD arising after solid organ 
transplant (SOT) involved 32 patients refractory to conventional treatment; complete 
remission was achieved in 14 cases (12). Regarding PTLD after hematopoietic stem cell 
transplant (HSCT), complete remission was achieved in 11 out of 13 patients (13), 7 out 
of 10 patients (14), 3 out of 6 patients (15), and  12 out of 17 patients (16). EBV-specific 
ATCT was also used as pre-emptive therapy on reactivation of EBV before onset of 
disease. A retrospective analysis showed that none of the 101 HSCT recipients receiving 
EBV-specific CTLs developed PTLD, compared to 5 out of the 42 that received no 
prophylaxis (17). 
Adoptive T cell immunotherapy for EBV-associated tumours seems therefore to be a 
safe and effective treatment for patients not responding to conventional therapy.  
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For PTLD arising after HSCT, EBV-specific CTL were mostly generated from PBMC 
derived from the original HLA-matched stem cell donors. However, in settings where 
the donor is EBV-negative or is not available, such as after cadaveric SOT, umbilical 
cord blood transplant, or in patients with EBV-associated solid tumours, one solution is 
to resort to third party donors. Several trials using third party cells have proved effective. 
ATCT with T lymphocytes from third party donors was effective in 5 cases out of 6 with 
severe infection (18). In another study, two patients with PTLD after HSCT receiving in 
vitro expanded EBV-specific CTLs from third party donors showed complete remission 
(19). A further trial, including third party donors, confirmed the efficacy of this 
approach (16). No graft versus host disease (GVHD) attributable to the ATCT was 
reported. 
Since infusion of cells from third party donors puts the patient at risk of GVHD, it is 
critical to infuse T lymphocytes that have been selected for their antigen specificity with 
minimal contamination by non-specfic and potentially alloreactive T cells. So far two 
techniques with clinical grade reagents are available for isolation of antigen-specific T 
lymphocytes: IFN capture antibodies and HLA-multimers for immunomagnetic 
selection. Both methods proved to be effective without increasing alloreactivity 
(14,15,18).  
On these basis the creation of a registry of third party donors of known HLA type, and 
with high levels of circulating EBV-specific T lymphocytes, should ensure the rapid 
availability of cells for ATCT. 
A crucial consideration in EBV-specific T-cell immunotherapy is the choice of antigens 
to be targeted by the infused T lymphocytes. It is widely assumed that, as in other EBV-
associated tumours, lytic antigens are not expressed in PTLD. However several studies 
indicate that these antigens are expressed. Lytic antigens, predominantly BZLF1, were 
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detected by immunohystochemistry in PTLD specimens (20,21). In other studies 
transcripts of lytic antigens were found in high percentages of PTLD cases (22,23). 
Moreover, CTL recognition of lytic antigens seems to correlate with resolution of the 
tumour with conventional therapy (23). Therefore, lytic antigens should not be 
dismissed as suitable targets of EBV-specific T-cell ATCT in PTLD.  
Recent emerging evidence suggests that, besides CD8+ T lymphocytes, CD4+ T cells are 
also important for effective ATCT.  In fact, the Class II-restricted antigenic repertoire 
for the EBV epitopes is broader than the Class I-restricted repertoire. Cytolytic CD4+ T 
lymphocytes specific for lytic epitopes effectively lyse LCL cells in vitro (24), and a 
better response to T-cell immunotherapy in PTLD seems to be related to a higher 
number of EBV-specific CD4+ lymphocytes in the infused sample (12). These data 
support the targeting of Class II epitopes for EBV-specific T-cell immunotherapy. 
So far expanded polyspecific CTL, which include lots of redundant specificities, have 
been used. A more targeted, epitope-specific approach is still innovative and to be 
tested. This is cheaper than engineering T cells, and it is easier to get approval, because 
the cells are minimally manipulated and with low risk profile. 
On the basis of the considerations addressed above, we set up a panel of HLA-typed 
donors with high levels of circulating CD4+ and CD8+ T lymphocytes recognising both 
latent and lytic EBV epitopes. In addition to the magnitude of EBV-specific responses 
we have characterised the selectabilty of EBV T cells using different selection methods, 
and the effector functionality of ex vivo selected, minimally manipulated T cells. Our 
data demonstrate the feasibility of establishing a registry of HLA-typed third party 





2.3. MATERIALS AND METHODS 
 
2.3.1. PEPTIDES 
The peptides were selected on the basis of: i) being able to induce a significant T-cell 
response, and ii) being restricted to the HLA Class I and Class II alleles that are the most 
common in the UK population. HLA A02, A11, B07, B08, B44, DR03, DR04, DR07, 
DR13, DQ05 and DP04 were identified as the HLA alleles most frequently expressed 
(25). Care was taken to select peptides derived from lytic together with peptides derived 
from latent EBV antigens, and restricted to either HLA Class I or Class II. The chosen 
peptides are shown in Table 2.1.  
 
 
Table 2.1. List of the EBV-derived peptides used in this study. (From 29). 
CLASS I RESTRICTED CLASS II RESTRICTED 
Peptide Allele Protein Peptide Allele Protein 
SVRDRLARL A2 EBNA3A VKLTMEYDDKVSKSH DR0301 BMRF1 
FLYALALLL A2 LMP2 PYYVVDLSVRGM DR4 BHRF1 
LLWTLVVLL A0201 LMP2 PGNDSTVQTAAAVVF DR13 BZLF1 
CLGGLLTMV A0201 LMP2 VYGGSKTSLYNLRRGTALAI DR7 EBNA1 
YVLDHLIVV A0201 BRLF1 PRSPTVFYNIPPMPLPPSQL DR7 + 52b EBNA2 
GLCTLVAML A0201 BMLF1 MVFLQTHIFAEVLKD DR15 EBNA1 
TLDYKPLSV A0201 BMRF1 LDLDFGQLTPHTKAVYQPRG DR15 BLLF1 
RLRAEAQVK A0301 EBNA3A LEKQLFYYIGTMLPNTRPHS* DR51 BXLF2 
IVTDFSVIK A11 EBNA3B LTAYHVSTAPTGSWF* DR52b BZLF1 
SSCSSCPLSK A11 LMP2 ILRQLLTGGVKKGRPSLKLQ* DR53 EBNA3B 
RPPIFIRRL B0702 EBNA3A SDDELPYIDPNMEPV* DQ5 EBNA3C 
QPRAPIRPI B0702 EBNA3C GSFSVEDLFGANLNRYAWHR* DP4 BKRF2 
FLRGRAYGL B8 EBNA3A     
QAKWRLQTL B0801 EBNA3A     
RAKFKQLL B0801 BZLF1     
KEHVIQNAF B4402 EBNA3C     
EENLLDFVRF B4402 EBNA3C       
Blue: latent antigens; red: lytic antigens.  





The peptides (Biosynthesis, Lewisville, TX, USA) were all dissolved in dimethyl 
sulfoxide (DMSO) at 10 mg/ml stock solution. 
 
2.3.2. DONORS 
Platelet donors undergoing apheresis at the NHS Blood Donor Centre, Birmingham, UK 
were screened on the basis of their HLA typing. The typing of the HLA A, B, C and 
DR1 loci was available for all the donors, while the typing of the remaining loci was 
largely incomplete. 108 donors expressing at least one of the alleles representing the 
restricting element for the above mentioned peptides were selected for our study. 
Informed consent was sought from each donor prior to sample collection. Before 
platelets apheresis, each donor was bled, and 5 ml of coagulated blood was colected for 
serum separation. After apheresis, the leukocyte-containing cone, a by-product of 
platelet apheresis, was collected and peripheral blood mononuclear cells (PBMC) 
isolated.  
The project was approved by the NRES committee West Midlands, REC ref 
11/WM/0315. 
 
2.3.3. SERUM AND CELL COLLECTION 
A tube with coagulated blood was centrifuged at 500 g for 10 min, and serum was 
collected. 
Leukocyte-enriched blood was collected from apheresis cones with a syringe, diluted 1:2 
with sterile phosphate buffer solution (PBS), and a Ficoll gradient separation was 
performed. PBMC were collected, washed and resuspended in RPMI1640 plus 10 % 





A standard IFN Elispot was performed using the Elispot Assay for Human Interferon- 
(Mabtech, Nacka Strand, Sweden), according to manufacturer’s instructions. Briefly, 
MAIPN45 Elispot plates (Millipore, Billerica, MA, USA) were first treated for 1 min 
with 30 % ethanol. The primary antibody was then added and incubated overnight at 4 
C. After washing, 105 PBMC for Class I-restricted peptides and 5x105 PBMC for Class 
II-restricted peptides were seeded in each well. Peptides were added at a final 
concentration of 40 and 80 g/ml for Class I- and Class II-restricted peptides, 
respectively; as positive control phytohemagglutinin (PHA) was used, whilst DMSO 
was used to establish background level. After 24 hrs in a CO2 incubator, plates were 
washed and incubated for 2 hrs at RT with the secondary antibody. Afterward, plates 
were washed and incubated for 1 hr at RT with the streptavidin-alkaline phosphatase 
conjugate. Staining was performed using the AP Conjugate Substrate Kit (Bio-Rad, 
Hercules, CA, USA), exactly following manufacturer’s instructions. Dots were counted 
on an AID Elispot reader (Autoimmun Diagnostika, Strassberg, Germany). Each test 
was performed in duplicate, and repeated in case of inconsistency between the readings. 
Since donors were not HLA typed for DQ and DP genes, nor for DR genes other than 
DRβ1, PBMC from all the selected donors were tested for reactivity against all the 
peptides restricted to DR51, DR52, DR53, DQ05 and DP04. 
 
4.3.5. FLOW CYTOMETRY 
For intracellular IFN staining, cells were first stimulated with peptide at the 
concentrations used for Elispot, and 1 h later 1 l/ml Golgi Stop (BD, Franklin Lakes, 
NJ, USA) was added. After overnight incubation cells were fixed and permeabilised 
using Fix & Perm Kit (An Der Grub, Kaumberg, Austria), and stained with anti CD3 
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PE, anti CD4 PE-Cy7, anti IFN APC (all from BD), and anti CD8 APC-eFluor 780 
(eBioscience, San Diego, CA, USA). For staining with GLC Dextramers (Immudex, 
Copenhagen, Denmark), manufacturer’s instructions were followed. Briefly, 106 PBMC 
were incubated with 10 l GLC Dextramer at RT in the dark for 10 min, then anti CD3 
PE, 7AAD (BD) and anti CD8 APC-eFluor 780 were added. After 20 min at RT in the 






















2.4.1. IFN ELISPOT IS A SUITABLE TECHNIQUE FOR 
SCREENING T-CELL RESPONSE TO EBV 
Preliminary experiments were carried out in order to identify the technique best suited 
for screening T-cell response to EBV-derived peptides in PBMC from healthy people. 
Three techniques were taken into account: Dextramer staining, IFN Elispot, and 
intracellular IFN staining.  
PBMC from two donors were activated with a pool of peptides, and Elispot and 
intracellular IFN staining were performed in parallel (Figure 2.1A). While a specific 
response for both Class I and Class II could be detected with Elispot, no difference 
between unstimulated and stimulated cells was found using intracellular IFN staining.  
Dextramer staining and Elispot were then compared (Figure 2.1B). A specific response 
to GLC peptide was found with Elispot, and a specific staining was detected with the 
GLC Dextramer. 
It is of note that the percentage of GLC-specific PBMC detected with the two techniques 
is very close, indicating that they have roughly the same sensitivity. 
Since Elispot is less expensive than multimer staining, and allows for the detection of all 
the Class II-restricted peptides in our panel, we used this technique to screen our cohort 








    
                                                                                                                                
 
Figure 2.1. Comparison of different techniques for the enumeration of EBV-
specific T lymphocytes. (A) PBMC were incubated with a pool of either Class I-
restricted or Class II-restricted peptides, afterward IFN Elispot and intracellular IFN 
staining were performed. For the latter technique the percentage of CD8+ T lymphocytes 
expressing high levels of IFN is indicated. Single representative experiment out of two. 
(B) PBMC from two donors were incubated with GLC peptide and either Elispot was 

























2.4.2. THERE IS AN INTRA- AND INTER-DONOR VARIABILITY 
IN THE RESPONSE TO EBV PEPTIDES 
Elispot was performed on the 108 healthy donors enrolled in our study, using 17 HLA 
Class I-restricted peptides, 13 derived from latent and 4 from lytic proteins, and 12 HLA 
Class II-restricted peptides, 5 from latent and 7 from lytic proteins. Since most of the 
donors were not typed for the HLA Class II loci, with the exception of DRB1, the 
peptides not restricted to DRB1 gene products were tested on all the donors. 
Table 2.2 summarizes the results obtained. We found a large difference in the amplitude 
of response to the different peptides within the same donor, but there was also a quite 
relevant difference in the responses elicited by the same peptide in different donors. 
Despite this remarkable inter-individual variability, we were able to detect at least one 
high-responding donor for all the peptides in our panel.  
However, 14 donors did not react to any of the peptides they were tested against. Since 
our donors were not checked for the positivity to EBV, it likely that these non-




Table 2.2. Evaluation of T-cell response to EBV epitopes in a panel of healthy 
donors. (From 29). 
 
White cell: not tested (the donor did not express the restricting HLA allele); green cell: 
no response (below 2 times the background); yellow cell: weak response (between 2 and 
5 times background); amber cell: strong response (above 5 times background); red cell: 





2.4.3. THERE ARE DOMINANT AND SUBDOMINANT PEPTIDES 
Although the reactivity to a given peptide in each donor was absolutely unpredictable, 
we found that there is a hierarchy among both Class I- and Class II-restricted peptides 
(Table 2.3). For the former set of peptides the frequency of donors responding to RAK 
was 12 times the frequency of donors responding to SVR. This phenomenon also occurs 
for Class II-restricted peptides, but is less evident. 
 
    Table 2.3. Frequency of positive response to the different peptides. (From 29). 
 
CLASS I RESTRICTED CLASS II RESTRICTED 
Peptide Allele Frequency % Peptide Allele Frequency % 
RAK B0801 22/28 78.6 GSF DP4 58/108a 53.7 
GLC A0201 30/44 68.2 PYY DR4 15/28 53,6 
RPP B0702 16/26 61.5 PRS DR7+52b 8/16 50.0 
FLR B8 17/28 60.7 LEK DR51 51/108 47.2 
IVT A11 5/10 50 VYG DR7 7/16 43.8 
EEN B4402 12/37 32.4 LDL DR15 7/16 43.8 
YVL A0201 14/44 31.8 SDD DQ5 46/108 43.8 
QAK B0801 8/28 28.6 LTA DR52 47/108 43.5 
CLG A0201 10/44 22.7 MVF DR15 6/17 35.3 
RLR A0301 7/32 21.9 VKL DR3 6/20 30.0 
QPR B0702 5/26 19.2 ILR DR53 26/108 24.1 
KEH B4402 7/37 18.9 PGN DR13 2/9 22.2 
LLW A0201 6/44 13.6     
FLY A2 6/44 13.6     
TLD A0201 5/44 11.4     
SSC A11 1/10 10     
SVR A2 3/44 6.8         
      




It has to be noted that for some peptides the restricting allele was defined at molecular 
level, while for others the restricting antigen was identified by serology. An attempt to 
predict the restricting allele for the latter peptides using three algorithms available on 
line, i.e. SYFPETHI, DTU (http://www.cbs.dtu.dk/services/NetMHCpan-3.0/) and IEDB 
(http://tools.immuneepitope.org/mhci/) gave disappointing results, since all the 
algorithms allowed for the analysis to be carried out only on a very limited set of alleles. 
As an example, regarding the many alleles encompassed by the antigen HLA-A2 
SYFPETHI and DTU provide prediction for the sole allele A*02:01 and IEDB for 
A*02:01 and A*02:06. 
Instead, good correspondence was observed when the predictions were compared with 
the nominal restricting element resulting from laboratory data. For instance, the peptides 
LLWTLVVLL and GLCTLVAML, nominally restriced to the allele A*02:01 (25,26), 




        Table 2.4. Comparison of three predictive algorithms 
         
        aarbitrary score, the highest the value, the highest the affinity 
        bpercentile rank, the lowest the value, the highest the affinity 
 
The degeneration of the common motives did not allow for such an analysis 
to be also performed with satisfactory results on Class II alleles. 
Peptide HLA allele SYFPEITHI IEDB DTU
LLWTLVVLL A*02:01 5 0.3 0.4
LLWTLVVLL A*03:01 NA 11.05 11
GLCTLVAML A*02:01 3 2.3 1.1
GLCTLVAML A*03:01 NA 19 19
a b                                     b
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2.4.4. THE RESPONSE TO SOME CLASS II-RESTRICTED 
PEPTIDES SEEMS TO BE PROMISCUOUS 
In 8 cases we recorded a concomitant strong response to LEK, LTA and ILR (Table 
2.2). Since an individual can express only up to two HLA molecules among DR51, 
DR52 and DR53, this finding suggests the occurrence for these peptides of a 
promiscuous response. The same conclusion can be drawn from the observation of a 


















With a series of preliminary experiments we found that intracellular IFN staining is less 
sensitive than Elispot and Dextramers for screening T-cell response to EBV-derived 
peptides, whilst the sensitivity of the two latter techniques is similar. Considerations on 
costs and logistics of bulk testing prompted us to choose Elispot over HLA multimers, 
and with this technique we have assayed a panel of 108 healthy donors for the reactivity 
of their T lymphocytes to EBV-derived peptides restricted to the HLA alleles that are the 
most common in the UK population.  
14 donors did not respond to any of the peptides tested. As platelet donors are not tested 
for EBV, we cannot say whether these donors were EBV-negative or reacted to peptides 
other than those we tested. In order to establish a registry of third party donor, the EBV 
serostatus should be tested. 
The remaining 94 donors responded to one or more peptides. We could find at least one 
donor with a strong response for each of the peptides tested. In general we detected a 
remarkable intra- and inter-donor variability, i.e. a single donor reacting differently to 
different peptides, and different donors mounting different response to the same peptide. 
It has also to be noted that we had strong responses to peptides derived from both lytic 
and latent EBV antigens.  
Although the individual response to a given peptide is unpredictable, a hierarchy is 
identifiable with some peptides being able to induce response in most cases, and others 
in only a few. This holds true particularly for Class I-restricted peptides, where the 
responses span from 81.5 to 6.8 %.  With Class II-restricted peptides we found that the 
magnitude of responses was comparable to Class I. However, in some instances we had 
evidence that the response to Class II-restricted peptides was promiscuous, involving 
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alleles other than the cognate ones. This might be related to the fact that the long Class 
II-restricted peptides may harbour in their sequence epitopes for more than one allele, or 
that they may undergo proteolytic cleavage during incubation, generating new epitopes, 
including Class I restricted ones. Promiscuity in the response to SDD and GSF peptides 
might in part explain the high percentage of responders: since the percentage of DQ05 
and DP04 in UK population is about 50 % (27), either all the individuals expressing 
these antigens responded to by chance EBV, or other HLA alleles were also involved. 
More studies are required to elucidate this point.  
The algorithms we examined proved effective in predicting the peptide affinity for the 
HLA Class I alleles that are in their data base but these data bases are largely incomplete 
and do not allow to unmistakably identify for most peptides the restricting HLA allele.   
In general our data demonstrate the feasibility of establishing a registry of HLA-typed 
third party donors for T-cell ATCT in EBV-associated diseases.  Indeed, the 
establishment of an allogenic T-cell donor registry will greatly facilitate T-cell ATCT in 
a number of virus-associated diseases (28), providing at short notice fresh EBV-specific 
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The memory T-cell pool is essential for long-term health. Antigen-experienced CD8+ T 
cells with a naïve (TN) phenotype and stem cell features, T-memory stem cells (TSCM) 
and memory T cells with naïve phenotype (TMNP), have been described as contributing 
to the maintenance of the pool, but the mechanisms underlying their generation remain 
unknown. Primary antigen stimulation of T cells is believed to trigger a one-way 
differentiation from TN to memory T-cell subsets. However, we demonstrated that 
recently differentiated central memory and effector memory T cells can de-differentiate 
into cells with a revertant TN-like phenotype (TNrev) in the presence of homeostatic 
cytokines, of which IL-7 was the most potent. Despite the naïve phenotype, molecular 
analysis showed that TNrev had an activated T-memory profile. Functionally TNrev 
displayed the same characteristics as TSCM and TMNP, including high proliferative and 
differentiative capacity, polyfunctionality and cytolytic activity upon re-stimulation. 
They could undergo multiple cycles of differentiation and reversion. Depending on 
cytokine milieu, TNrev acquired the phenotype of TSCM or TMNP, which we suggest are the 
same cells exposed to different environmental conditions. We propose that cytokine-
dependent reversion of recently differentiated CD8+ T cells represents a novel 
mechanism for replenishing the human memory T-cell pool, contributing to the 










The development of the memory T-cell pool is essential for long-term health and 
survival, but how this is maintained remains unresolved. Thymic output is age-limited 
and considered insufficient for maintaining the TCR repertoire. Current CD8+ T-cell 
differentiation models presume a one-way pathway (1) where initial antigen stimulation 
triggers differentiation from naive (TN) to central memory (TCM), effector memory 
(TEM), and effector (TEff) T cells. Along this pathway, CD8
+ T cells acquire increasing 
effector function but progressively loose survival and proliferative capacity.   
However, two subsets of phenotypically naïve CD8+ T cells with stem cell features and 
memory traits that have enhanced differentiative and proliferative potential have been 
recently described. 
T-memory stem cells (TSCM) have been proposed to constitute the precursor memory T-
cell pool, which lies between TN and TCM in the differentiation pathway (2).  Despite 
displaying some phenotypic features in common with TN cells and showing ability of 
self-renewal, TSCM exhibit functional characteristics of antigen-experienced cells and 
rapidly differentiate into memory and TEff subsets upon antigenic re-challenge.   
The recently described memory T cells with naïve phenotype (TMNP) also represent a 
subset of antigen-experienced CD8+ T cells with naïve phenotype, high proliferative 
potential and polyfunctional capability (3).  Half of these cells express granzyme B 
(GrB), a molecule thought to be expressed only by TEM and TEFF (4). Despite sharing 
several phenotypic and functional characteristics, TSCM and TMNP differ in their extended 
phenotype, particularly in the expression of CD95, and it is not clear whether they 
represent different T-cell subsets (3) or are the same cells transiently exhibiting different 
membrane markers for contingent reasons. Moreover, the mechanisms leading to the 
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generation of these cell subsets still need to be fully elucidated. Although CD8+ TSCM 
can be produced in vitro by activating TN cells with interleukin (IL)-7, IL-21, and the 
glycogen synthase-3β inhibitor TWS119 (5), the physiological mechanisms generating 
these cells are unknown. As for TMNP, nothing is known about their origin. 
Given the importance of cytokines as key regulators of T-cell mediated immunity, we 
analyzed the effect of different cytokines on the pattern of T-cell differentiation after 
initial stimulation. We used lymphocytes from human cord blood (CB) which are less 
likely to have encountered antigens and have a very low frequency of TSCM (2). We 
demonstrated, for the first time, that recently differentiated CD8+ memory T cells can 
revert to a naïve-like phenotype in a process that is controlled by a hierarchy of g-chain 
(c) cytokines, the most potent of which is IL-7. We show that these revertant CD8+ TN 
cells (TNrev) transiently share phenotypic and functional characteristics with TSCM and 
TMNP, before displaying a trend to re-acquire a phenotype similar to primary TN cells. 
Collectively, our study unravels the mechanism generating TSCM and TMNP and provides 
a unifying theory for these subsets, and identifies a novel model for human CD8+ T-cell 
differentiation/de-differentiation with important biological implication for understanding 














3.3.1. IL-7 INDUCES RECENTLY DIFFERENTIATED CD8+ 
MEMORY T CELLS TO REVERT TO A NAÏVE-LIKE 
PHENOTYPE. 
 
Cord Blood Mononuclear Cells (CBMCs) were activated with anti-CD3 plus IL-2 and 
the differentiation of CD8+ T cells was monitored following CD45RA and CCR7 
expression. These markers are conventionally used to categorize T cells into TN 
(CD45RA+/CCR7+), TCM (CD45RA
-/CCR7+), TEM (CD45RA
-/CCR7-) and TEff 
(CD45RA+/CCR7-) subsets (1). As expected, activation induced an expansion of TCM 
and TEM subsets with a concurrent reduction in TN (Fig. 3.1A,B). TEff were not generated 
in significant number following one single stimulation and were not considered further.   
In order to investigate the role of cytokines in modulating the differentiation of T cells 
after activation, IL-7 was added to the culture medium when the proportion of CD8+ TN 
dropped below 20%, usually a week after activation (6.7 ± 1.91 days, mean ± 1 SD, 
n=50).  In the first three days following addition of IL-7, the percentage of CD8+ TN 
continued to diminish, reaching a nadir of 8.39% ± 6.40 (Fig. 3.1B). However, after 
further incubation with IL-7 the great majority of CD8+ T cells started to re-express 
CD45RA and reverted back to a phenotype resembling TN, characterized by co-
expression of CD45RA, CCR7, CD62L and CD27 and lack of expression of CD45RO 
(Fig. 3.1A and Supplemental Information Appendix, Fig. S1).  
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Fig. 3.1. IL-7 induces reversion of recently differentiated memory CD8+ T cells to a 
naïve-like phenotype. (A) Flow cytometric analysis of phenotypic changes in CD8+ T 
cells after activation and successive incubation with IL-7. CBMCs were activated with 
anti CD3 and the phenotype of CD8+ T-cell was monitored over time. At day 5, when 
the percentage of TN dropped below 20%, IL7 was added to the cultures. Numbers 
indicate the percentage of cells in each quadrant. Single representative experiment out of 
50. (B) Kinetics of phenotype reversion of CD8+ T cells from 50 different CB samples. 
The shaded area represents the times when IL-7 was added for the first time. (C) CD8+ 
T-cell proliferation after activation and after IL-7 administration. CBMCs were stained 
with CFSE either before activation (left panels) or at day 14, during phenotype reversion 
(right panels). At the indicated time points, cell phenotype and CFSE content were 
assessed for TN (light gray dots) and TCM (dark gray dots). Dashed lines indicate basal 
content in CFSE. Single representative experiment out of three. (D) Flow cytometry 
evaluation of IL-7-dependent phenotype reversion in recently differentiated TCM and 
TEM. Enriched CD8
+ TN were stimulated and, when TN percentage dropped below 20%, 
untouched TCM and TEM were isolated. The two cell subpopulations were then incubated 
with IL-7 and monitored for phenotype changes over time. The TCM and TEM shown here 
are from two different CB samples. Single representative experiment out of three, for 





The re-acquisition of a naive phenotype by CD8+ memory T cells reached a plateau by 
13-28 days after initial activation (19.8 ±4.66 days), and typically represented over 70% 
of the CD8+ T-cell population (mean 71.1% ±11.68, range 44.7%- 95.3%). As such, this 
value was only slightly below the mean of 86.6 % of CD8+ TN at day 0 (±5.84, range 
74.3-97.7). We called TNrev the cells that had reverted to a naïve-like phenotype. 
Although all samples followed a similar pattern, there was significant variation in the 
time taken to reach nadir in TN and peak in TNrev levels, and in the magnitude of the TNrev 
population at plateau (Fig. 3.1B).  
To demonstrate that the phenotypic reversion of differentiated T cells was not due to 
enhanced proliferation or selective death of individual T-cell subsets, we enumerated the 
cells within each cell subset and monitored their proliferation. The total number of all 
cell subsets before and after reversion remained largely unchanged (Supplemental 
Information Appendix, Table S1), and no cell proliferation was detected after the 
addition of IL-7 and during phenotype reversion (Fig. 3.1C).  
To confirm that the phenomenon was due to modulation of cellular phenotype, recently 
differentiated CD8+ TCM and TEM were purified and incubated with IL-7. Phenotype 
reversion was again demonstrated for over 80% of the purified TCM and TEM, with the 







3.3.2. PHENOTYPIC REVERSION IS SUPPORTED BY 
CYTOKINES THAT MAINTAIN CELL SURVIVAL AND 
TNREV CAN UNDERGO SEVERAL ROUNDS OF 
REVERSION. 
 
We next assessed whether this property was unique to IL-7 or shared by other cytokines. 
Recently differentiated CBMCs were incubated with single and multiple combinations 
of the c cytokines IL-2, IL-7, IL-15, IL-4 and IL-21. IL-6, an inflammatory cytokine 
that is known to deliver pro-apoptotic signals, was also incorporated.  
Phenotypic reversion was indeed observed for several of these cultures but it was less 
marked than with IL-7 (Table 3.1). 
 
 




AThe percentage of CD8+ T cells within each subset at TN nadir and TNrev plateau is shown. 
 
 
Interestingly, CD8+ T cells cultured with IL-6 or IL-21 were driven toward a more 
differentiated phenotype with a substantial increase in TEff cells. No synergistic effect 
was observed when IL-7 was administered together with IL-2, IL-4 or IL-15. Of further 
interest was the observation that the ability of individual cytokines to promote de-
differentiation to TNrev cells correlated with their ability to support CD8
+ T-cell survival 
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in vitro (Fig. 3.2A). Particularly the use of IL-6, IL-21, or medium alone led to massive 
cell death. This suggests that reversion may be a default physiological program of 
recently differentiated CD8+ T cells when a survival stimulus is provided.  
Phenotypic reversion also takes place following differentiation induced by mitogenic 
stimuli other than soluble anti-CD3 (Fig. 3.2B). 
The percentages of differentiated CD8+ T cells undergoing IL-7-dependent phenotype 
reversion after activation with PHA and SEB were similar to those found in cells 
activated with anti-CD3. Activation with CD3/CD28 beads led to a smaller proportion 
of differentiated cells reverting to a naïve phenotype. However, in these experiments we 
were unable to fully remove the beads, some of which were still attached to the cells 
when IL-7 was added. It is possible that the resulting continuous stimulation may 
explain the lower degree of reversion achieved. Indeed, the CD8+ T cells activated with 
anti-CD3 alone and those activated with anti-CD3 plus cross-linked anti-CD28 showed 
similar kinetics of reversion, demonstrating that co-stimulation did not prevent the cells 
from reverting their phenotype.  
Further, we assessed whether cells could undergo more than one cycle of phenotypic 
reversion. Since serial rounds of anti-CD3 stimulation led to a high rate of cell death, 
PHA was used for two further rounds of activation; each was followed by IL-7 
incubation (Fig. 3.2C). After each cycle of activation and IL-7 treatment, a phenotype 
reversion was observed, indicating CD8+ TN can undergo repeated cycles of 
differentiation and de-differentiation. 
In order to demonstrate that phenotypic reversion is possible after activation with 
cognate antigen, CBMCs were transduced with a gene encoding a TCR specific for the 
SSC peptide (6). Following activation and retroviral transduction, cells acquired a 






Fig. 3.2. Phenotype reversion can be induced by cytokines other than IL-7 and 
following activation with different stimuli. (A) Viability of cells incubated with 
different cytokines. Activated CBMCs were incubated from day 4 with each cytokine or 
medium, and CD8+ T-cell viability was evaluated by flow cytometry using 7-AAD 
uptake. Data are represented as means ± 1SD of three samples. (B) The kinetics of 
phenotype reversion of CD8+ T cells activated with different artificial stimuli. IL-7 was 
added on day 6, and CD8+ T-cell phenotype was monitored throughout. Data are 
represented as means ± 1SD of three samples. (C) The kinetics of phenotype reversion 
of CD8+ T cells undergoing successive cycles of actvation/IL-7 incubation. Newly 
generated CD8+ TNrev cells were twice re-stimulated with PHA and induced to revert 
twice with IL-7 when the percentage of TN dropped below 20%. (D) Flow cytometry 
analysis of phenotype changes of CD8+ TNrev upon activation with the cognate antigen. 
CB T-lymphocytes were activated, retrovirally-transduced with the SSC-TCR and 
induced to revert their phenotype with IL-7 (left panels). Afterward, cells were 
incubated with peptide-pulsed DCs to induce specific differentiation of transduced cells 
(central panels). IL-7 was then added again, driving the transduced cells to revert their 
phenotype (right panels). Plots were gated on CD8+ T cells. The upper panels show the 




Cells were then re-challenged with SSC-pulsed autologous DCs which differentiated 
them again to CD8+ TEM within 5 days (Fig.3. 2D). At this point IL-7 was re-added, and 
after a further 9 days a second reversion to TNrev was attained, demonstrating that 
phenotype reversion was also possible after stimulation with cognate antigen presented 
by professional antigen-presenting cells. 
 
 
3.3.3. CD8+ TNREV PROLIFERATE AND DIFFERENTIATE 
RAPIDLY INTO FUNCTIONAL EFFECTOR CELLS 
FOLLOWING SECONDARY STIMULATION. 
Since T cells progressing along the differentiation pathway increasingly lose their ability 
to proliferate (Klebanoff et al., 2006), and since TNrev are antigen-experienced cells that 
have undergo differentiation and expansion, it might be expected that they would have 
diminished proliferative potential when compared to primary TN.   
The ability to differentiate and proliferate over time upon re-stimulation was therefore 
checked in TNrev and TN.  TNrev differentiated into memory subsets more rapidly than TN, 
acquiring at the same time point a more differentiated phenotype (Fig. 3.3A). They also 
exhibited a higher proliferation rate (Fig. 3.3B).  
The capacity to achieve a more differentiated stage suggested that TNrev might also 
acquire effector function following re-stimulation. To check this hypothesis CB T-
lymphocytes were activated, retrovirally-transduced with the SSC-TCR and induced to 
revert their phenotype with IL-7. These SSC-specific TNrev were then re-stimulated with 
peptide-pulsed DCs.  Once reaching the TEM phenotype, the cells expressed intracellular 
perforin and GrB (Fig. 3.3C). Moreover, in a standard 51Cr release assay, they exerted                    
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cytolytic activity against SSC-loaded, HLA A*1101-transduced T2 target cells (Fig. 
3.3D). 
 
                        
Fig. 3.3. CD8+ TNrev cells have excellent differentiative and proliferative potential, 
and can acquire effector function upon secondary activation. (A) Flow cytometry 
analysis comparing the kinetics of phenotype change in CD8+ TNrev and TN cells from 
the same CB sample following activation with PHA. Single representative experiment 
out of three. (B) Flow cytometry analysis of the proliferation of CD8+ TNrev and TN cells. 
Cells from the samples shown in the panel above were stained with CFSE at day 0 and 
activated with PHA. The CFSE content in the two cell subsets is shown at the indicated 
time points. Dashed lines represent basal content of CFSE. Single representative 
experiment out of three. (C) Flow cytometry analysis of perforin and GrB expression by 
the re-stimulated TCR-transduced CD8+ TNrev. The intracellular expression of perforin 
and GrB by TNrev cells transduced with the SSC-TCR were assessed after re-stimulating 
the cells twice with cognate peptide-pulsed DCs. Black histograms indicate resting 
CD8+ TNrev cells, gray indicate re-stimulated cells. (D) Cytotoxic assay of re-stimulated, 
SSC-specific TCR-transduced TNrev. The T cells were incubated in a standard 
51Cr 
cytolytic assay with target cells consisting of HLA A*1101-transduced T2 cells loaded 
with either 1 g/ml (diamonds), 10 ng/ml (squares) or 1 ng/ml (triangles) of SSC 
peptide. The peptide solvent, i.e. DMSO, was used as control (crosses). The percentage 
of target cell killing at different E:T ratios is indicated. (From 37). 
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3.3.4. REVERSION OCCURS IN CD8+ T CELLS DERIVED 
FROM BOTH CBMCS AND PBMCS. 
To check whether reversion also occurs in T cells from adult donors, CD8+ TN from PB 
and from CB were compared for their ability to revert. After activation, PB T cells were 
also found capable of reversion to TNrev, but the magnitude of reversion appeared to be 
smaller than from CB T cells (Fig. 3.4).  
 
 
                           
Fig. 3.4. PB-derived CD8+ TN cells revert less than CB-derived ones.  CD8+ TN were 
isolated from CB (upper panel) and adult PB (lower panel), activated with anti CD3 and 
incubated with IL-7 from day 5. The percentage of differentiation subsets was calculated 
for each cell source before and after reversion.  Data are represented as mean ± 1SD of 





3.3.5. CD8+ TNREV AND TN DIFFER AT THE A 
TRANSCRIPTOME LEVEL. 
To investigate the properties of CD8+ TNrev at the molecular level, and to identify distinct 
markers for these cells, the gene expression profiles of CD8+ TNrev were compared with 
those of TN.  
The analysis of the transcriptomes identified 1938 genes having statistically significant 
changes in expression levels (Supplemental Information Appendix, Table S2).  58.9% of 
these genes were over-expressed in TNrev, the rest in TN. 
At the cell level, the most significantly enriched pathways within TNrev are related to cell 
proliferation, cell cycle control and cell death (Fig. 3.5). These results are likely related 
to the fact that we compared activated with resting lymphocytes.  
Similarly, at the systemic level, the functions affected by the differential gene expression 
mainly reflect the activation states they represent (Fig. 3.5B), and TNrev showed an 
overall increase in the expression of genes involved in T-cell pathways affecting 
proliferation, migration and function of T-lymphocytes (Fig. 3.5C). 
These findings indicate that recently reverted TNrev are functionally quite distinct from 







Fig. 3.5. Functions and systems affected by differentially expressed genes in CD8+ 
TNrevand TN cells. Ingenuity Pathway Analysis was used to identify the pathways 
involved. (A) The pie-chart shows the molecular and cellular functions affected by the 
differentially expressed genes. (B) The pie-chart shows the physiological systems 
(development and function) affected by the differentially expressed genes. (C) 
Molecular network of genes involved in T-cell development. Red and green colors 
indicate increased and decreased expression, respectively. (D) Expression heat map of 
the genes encoding for putative markers for distinguishing TN, from TNrev. * indicates the 








3.3.6. TNREV HAVE MEMBRANE MARKERS DISTINCT 
FROM TN. 
 
Using the data from the microarray analysis and from literature (7-14), 28 membrane-
bound proteins were selected in order to identify distinct markers that could be used for 
discriminating TNrev from TN subsets.  
Fig. 3.5D shows the heat map of the RNA expression data from the microarray analysis 
for these markers.  
Afterward, the protein expression for these markers was measured by flow cytometry in 
the two subsets mentioned above, and in TCM. Most of these markers showed similar 
expression levels in both TNrev and TN (Supplemental Information Appendix, Fig. S2), 
proving useless for discriminating between these two cell subsets. Instead, integrin 7, 
CD95, CD25, CXCR3, and CD49d were expressed by TNrev only (Fig. 3.6A), which for 
these proteins showed expression levels similar to those found in TCM. 
Interestingly, CD95, CD25 and CXCR3 are also distinct markers of TSCM, and CD49d is 
a distinct marker of TMNP (2,3).  















Fig. 3.6. Comparative phenotype 
of CB CD8+ TNrev, TSCM and TN 
cells, and dependence on culture 
conditions. (A) The expression of 
the markers that discriminate early 
TNrev from TN was measured by flow 
cytometry. TN (black histograms), 
recently differentiated TCM (gray 
histograms) and early reverted TNrev 
(red histograms).  Single 
representative experiment out of 
three. (B) Kinetics of CD25 and 
CD127 expression by reverted CD8 
TNrev cells in the presence of either 
IL-2 or IL-7. After phenotype 
reversion had occurred following 
activation, cells were either 
maintained in 25 ng/ml IL-7 or 
switched to culture in 30 U/ml IL-2. 
The absence of one cytokine led to 
increased expression of its cognate 
receptor. The mean fluorescence 
intensity for CD25 and CD127 is 
shown. Data are represented as 
means ± 1SD of three samples. (C) 
Kinetics of the expression of 
discriminatory markers for early 
TNrev cells. The mean fluorescence 
intensity of integrin 7, CXCR3, 
CD95 and CD49d was monitored at 
different time points during 
activation and reversion as in (B). 
Data are represented as means ± 1SD 
of three samples. (D) 
Polyfunctionality of re-activated 
TNrev. TNrev were re-stimulated with 
PMA plus ionomycin, and the 
percentages of cells expressing GrB, 
IFN, TNF- and combinations 
thereof were measured after 3 and 14 
hours. Data are represented as mean 
of three samples. (E) Proposed 
model     of    CD8+    differentiation/ 
reversion. 
(From 37). 















3.3.7. CULTURE CONDITIONS INDUCE PHENOTYPIC 
AND FUNCTIONAL CHANGES IN TNrev. 
We next investigated if culture conditions could alter TNrev phenotype and function, and 
how TNrev relate to TSCM and TMNP. Here we will refer to the recently reverted TNrev that 
we have described so far as early TNrev, and to the revertants that have been incubated in 
long-term cultures, as late TNrev. We found that early CD8
+ TNrev cells had a phenotype 
that was very similar to the phenotype of TSCM, both being 
CD45RA+/CCR7+/CD62L+/CD27+/CXCR3+/CD31+/CD95+/CD122lo/CXCR4lo/CD45RO-
/CD69- (2), and to the phenotype of TMNP, both expressing  CD45RA
+/CCR7+/CD62L+/ 
CD27+/CXCR3+/CD31+/CD49d+/CD31+/CD122lo/CD45RO- (3). 
The only difference between early TNrev and the other two subsets was that TMNP are 
CD127+ and TSCM are CD127
+/CD25-, whilst TNrev are CD127
low/CD25high.  However, the 
expression of the receptors for IL-7 and IL-2 by T cells can be down-regulated by their 
respective cytokines (16,17). When early TNrev were deprived of IL-7 and maintained in 
IL-2, the cells shifted to a phenotype almost indistinguishable from TSCM and TMNP, with 
rapid decrease in CD25 expression and progressive increase in CD127 expression (Fig. 
3.6B). After a further two weeks culture with IL-2, we observed a progressive loss of 
CD49d, CD95, CXCR3 and integrin 7 (Fig. 3.6C), so that late TNrev acquired a 
phenotype approaching that of primary TN, displaying CD49d
-/CD95-/CXCR3-/integrin 
7-. We were unable to monitor the cells further, due to increased cell death. 
TMNP cells are functionally characterized by their ability to express GrB and secrete IFN 
and TNF- after re-stimulation for 3 hrs with PMA plus ionomycin (3). We used the 
same stimuli for re-stimulating early TNrev,. Although the cells were mainly GrB
+ or IFN+ 
or both, only a minority expressed TNF- (Fig. 3.6D). However, when re-stimulation was 
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continued up to 14 hrs, a sharp increase in the percentage of cells expressing all the three 
molecules was obtained. 
We suggest that TNrev, TSCM and TMNP belong to the same subset of early lineage T cells, 
where the minor differences in phenotype are related to the stage of activation and 
cytokine milieu. Given the considerable plasticity in early T-cell differentiation, we 
propose that the T-cell differentiation model should take into account the reversion of 
newly differentiated CD8+ T cells, from TEM to TCM and to TNrev/SCM/MNP, and possibly to 





















Here we described a previously unknown phenomenon of cytokine-driven reversion of 
newly generated memory CD8+ T cells into cells with TN-like phenotype, but with 
enhanced ability to proliferate, differentiate and acquire effector function upon re-
stimulation. We also identified the mechanisms by which these TNrev acquire function and 
phenotype of TSCM or TMNP. 
Self-renewal is a characteristic feature of TSCM, and this may be a correlate of the property 
of TNrev to revert repeatedly back to the TNrev stage after multiple rounds of stimulation. 
Like TMNP, TNrev became functionally lytic, expressed GrB, and secreted IFN and TNF- 
upon re-stimulation.  
Our experiments demonstrated that TNrev are endowed with remarkable plasticity, where 
phenotypic changes are dependant on the cytokine milieu and on the time in culture from 
antigenic stimulation. The difference in CD25 and CD127 expression between early TNrev, 
and TMNP and TSCM were related to exposure of the former cells to IL-7, which led to 
down-regulation of the cognate receptor (15-17). Replacing IL-7 with IL-2 led TNrev to 
express a phenotype that for these markers was indistinguishable from that of the other 
two cell subsets.   
 
The difference in the expression of CD95 between TMNP and TSCM is instead time-
dependant, and the TMNP phenotype corresponds to a later time point in the reversion 
process, where CD95 down-regulates.  
In contrast to CD95lo/CD49d+ TMNP, TSCM are CD95
+. Although CD49d expression by 
TSCM has not been previously described, we found that upon prolonged incubation CD95 
down-regulated more rapidly than CD49d, so that cells becoming CD95lo still retained 
high levels of CD49d. It is likely that TSCM represent an earlier stage than TMNP in the de-
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differentiation pathway. As such, we propose that early TNrev, TMNP and TSCM, despite the 
former cells being generated in vitro and the latter ones identified in vivo, belong to the 
same subset of recently differentiated T cells, but modulated by different cytokine milieu, 
and time from activation.   
 
Early TNrev retained phenotypic features typical of activated memory cells, including 
CD95, CD25, CXCR3, integrin 7 and CD49d expression (18-21), that correlate with 
their rapid functional response to stimulation. A further feature of CD8+ TNrev was the re-
expression of CD45RA, a critical regulator of the signaling threshold in T-lymphocytes 
(12, 22), which render TNrev more responsive to antigenic stimulation than TCM or TEM. 
We hypothesize that early TNrev cells are generated from recently differentiated TCM and 
TEM during the resolution of a viral infection. In this way an antigen-specific memory 
pool with heightened responsiveness to early infective re-challenge can be generated. 
Phenotype reversion would replenish the phenotypically naïve CD8+ T-cell pool, which 
would otherwise be depleted of the cells responding to the stimulating antigens if 
differentiation were a one-way process, and allow for the retention in this pool of antigen-
experienced cells. Indeed, besides the discovery of TMNP and TSCM, there is further 
evidence to support the concept that antigen-experienced T cells are contained within the 
naïve CD8+ T-cell pool: expanded populations of CD8+ TN specific for Cytomegalovirus, 
Epstein Barr virus or Influenza virus have been found in individuals positive for these 
viruses (23). Phenotype reversion may also explain how the TN pool remains preserved 
into old age, whilst the thymus involutes. Both in vivo analyses and mathematical 
modeling have shown that thymic output is insufficient to maintain the naïve T-cell pool 
in adults (24-26). Interestingly, the ability to revert was greater in CD8+ T cells derived 
from CB than from adults. This suggests that reversible CD8+ T cells may represent a 
subpopulation of TN that diminishes with age. This seems contrary to the finding that the 
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frequency of TMNP increases with age, but it can be explained by the fact that the latter 
cells respond to chronic viral infections. 
With time, early TNrev reverted further to a late TNrev stage, characterized by a 
CD95lo/integrin 7lo/CXCR3lo phenotype. Despite this trend, we cannot conclude that late 
TNrev cells can de-differentiate further, and the possibility for these cells to achieve a 
phenotype indistinguishable from primary TN remains a mere speculation. 
 
Our findings indicate that the generation of the human T-cell memory pool is a more 
complex phenomenon than hitherto thought, challenging the model of unidirectional T-
cell differentiation. Although the mechanism leading to the generation of TMNP is 
unknown, TSCM is thought to differentiate straight from TN (27), but we suggest that the 
current T-cell differentiation model should be modified to also take into account the 
reversion of memory T cells to TSCM/MNP/Nrev. Indeed, phenotypic reversion from TEM to 
TCM has been observed previously in murine models and in patients following 
hematopoietic stem cell transplant (HSCT) (28-30). Our model does not rule out the 
possibility that memory CD8+ T-cell precursors can also exist within different phenotypic 
subsets, such as TCM (31).  
 
The capacity to undergo reversion is likely an innate property of recently differentiated 
memory T cells, that becomes effective if cells are kept surviving long enough by 
‘survival’ cytokines, of which IL-7 was the most potent. Both IL-7 and IL-15 are known 
to promote the survival of memory CD8+ T cells (32), but IL-7 is unique in having a key 
role in providing survival signals and supporting homeostatic expansion of T cells during 
thymic differentiation (33, 34). IL-7 was also found to have a dominant role in the 
peripheral expansion of TSCM directly from TN in patients following HSCT (30, 35). IL-7 
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has therefore the ability to drive the generation of TSCM in both directions: from TN or 
through reversion from TCM or TEM.  
 
We propose that reversion is a critical physiological mechanism by which the pool of 
early antigen-specific memory T cells is replenished in order to maintain a competent 
immune system over the lifetime of an individual. Understanding this mechanism also 
permits the development of new methods for generating early lineage memory T cells for 
ATCT, which we have demonstrated with the transduction of an EBV-specific TCR, and 
where such cells used for immune receptor modification retain properties associated with 



















3.5. MATERIALS AND METHODS 
  
3.5.1 CELL SEPARATION AND CULTURE. 
The study was approved by the National Research Ethics Committee, UK REC no. 
11/WM/0315, and by the Non-Clinical Issue committee of the NHS Blood and 
Transplant.  Human CB from anonymized collections unsuitable for banking, was 
provided by the NHS Cord Blood Bank, UK, as Non-Clinical Issue. Peripheral blood 
(PB) was collected from consenting adult healthy blood donors from the NHS Blood and 
Transplant Donor Centre, Birmingham, UK.   
PB mononuclear cells (PBMCs) and CB mononuclear cells (CBMCs) were obtained by 
Ficoll separation. CD8+ TN and TNrev were enriched using the Naïve CD8
+ T-cell Isolation 
Kit (Miltenyi Biotech, Bergisch Gladbach, Germany). CD8+ TEM cells were negatively 
isolated after activation of enriched CD8+ TN by removal of CCR7
+ and CD45RA+ cells 
with anti-CCR7-APC, anti-CD45RA-APC and anti-APC MicroBeads (Miltenyi). CD8+ 
TCM cells were isolated from less differentiated samples by depletion of CD45RA
+ cells 
with anti CD45RA-APC and anti-APC MicroBeads. Cells were cultured in RPMI 1640 
plus 10% FCS. 
 
3.5.2. TCR GENE TRANSDUCTION. 
CBMCs were retrovirally transduced with a TCR, specific for the  SSCSSCPLSK (SSC) 
peptide of the LMP2 protein of Epstein Barr virus, as previously described.6 Also 
previously described are the generation of dendritic cells (DCs), their loading with the 




3.5.3. CELL ACTIVATION AND TREATMENT. 
Cells were activated, or re-activated, with either of the following stimuli. 
Anti-CD3: cells were incubated with 66 ng/ml anti-CD3 antibody (OKT3), plus 300 U/ml 
IL-2 (Miltenyi); cells were activated in this way throughout the study, unless otherwise 
indicated. 
Anti-CD3 and crosslinked anti-CD28: cells were incubated with 66 ng/ml OKT3, 66 
ng/ml LEAF anti-CD28 (BioLegend, San Diego, CA), and 66 ng/ml rat anti-mouse IgG1 
(BioLegend), plus 50 U/ml IL-2. CD3/CD28 beads: Dynabeads T Activator CD3/CD28 
(Life Technologies, Grand Island, NY) were incubated with CBMCs at 1:1 ratio in the 
presence of 30 U/ml IL-2. Phytohemagglutinin (PHA): cells were incubated with 1% 
PHA M (Life Technologies), plus 50 U/ml IL-2. Staphylococcus enterotoxin B (SEB): 
cells were incubated with 1 g/ml SEB (Sigma-Aldrich), plus 50 U/ml IL-2. From day 2, 
IL-2 100 U/ml, for soluble anti-CD3, or 30 U/ml, for the other cases, was added thrice a 
week. Phenotype was checked alternate daily. When the percentage of CCR7+/CD45RA+ 
CD8+ T cells dropped below 20%, half of the medium was replaced with fresh medium 
containing either IL-2, IL-4, IL-6, IL-7, IL-15 or IL-21 (all from Miltenyi), or 
combinations thereof, at final concentrations of 30 U/ml, 25 ng/ml, 10 ng/ml, 25 ng/ml, 
50 ng/ml, and 50 ng/ml, respectively. Thrice a week, half of the culture medium was 
replaced with new medium plus cytokine(s). Re-activation by phorbol myristate acetate 
(PMA) plus ionomycin was performed as previously described.3 
 
3.5.4. FLOW CYTOMETRY. 
The antibodies used for cell staining are listed in Supplemental Information Appendix, 
Table S3. Gating strategy involved selection of single cells and use of a “dump channel” 
including either 7-aminoactinomycin D (BD) and PerCP-conjugated CD14, CD16 and 
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CD19, or Live/Dead Fixable Violet (Thermo Fisher Scientific, Wilminghton, DE) and 
Pacific Blue-conjugated CD14, CD16 and CD19. Proliferation was evaluated by staining 
cells with 1 M CFSE. For intracellular staining, cells were fixed and permeabilized 
using the FIX&PERM kit (ADG, Kaumberg, Austria). In some experiments cells were 
enumerated using Trucount Beads (BD). Transduced lymphocytes were identified using 
HLA A*1101:SSC peptide-specific pentamers and Tag/PE (Proimmune, Oxford, UK). 
Flow cytometry was performed on either a FACSCanto II, or a Fortressa (BD). 
 
3.5.5. CYTOTOXICITY ASSAY. 
Cytotoxicity of transduced T cells was assessed in a standard 51Cr assay.6 Briefly, HLA 
A*1101-transduced T2 cells were loaded with different concentrations of SSC peptide, 
then used as targets at 2500 cells/well in a 5 hrs test. 
 
3.5.6. MICROARRAY ANALYSIS. 
Gene expression analysis was performed on 3 CD8+ TN and 3 CD8
+ TNrev samples. RNA 
extraction was performed using RNeasy columns (Qiagen, Hilden, Germany). Source 
RNA was confirmed as high quality by use of a Bioanalyzer 2100 (Agilent Technologies, 
Santa Clara, CA). RNA Integrity Numbers of 6.0 were confirmed for all samples using a 
RNA 6000 Pico Chip kit (Agilent). 25ng of each source sample RNA was labeled with 
Cy3 dye using the Low Input Quick Amp Labelling Kit (Agilent). A specific activity of 
greater than 6.0 was confirmed by measurement with a spectrophotometer. 600 ng of 
labeled RNA was hybridized to SurePrint G3 Human 8x60K microarray slides (Agilent). 
After hybridization, slides were scanned with a High Resolution C Scanner (Agilent), 
using a scan resolution of 3 mm. Feature extraction was performed using Feature 
Extraction Software (Agilent), with no background subtraction. Extracted data were 
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normalized using the R 3.0.1 software environment with the limma 3.16.8 analysis 
package (36). Log transformed expression values were analyzed using two class paired 
analysis, SAM v4.01.  
 
3.5.7. STATISTICS 
Differential gene expression was accepted as statistically significant if the False 
Discovery Rate was below 5% and the fold change in gene expression was >2. Functional 
and network analysis was performed on the pool of significant genes using Ingenuity 
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        Table S1. Cell numbers are not altered by phenotypic reversion. (From 37). 
               
 
               A Absolute number of CD8+ T cells within different subsets at TN nadir (days 6 and 8) and  
             TNrev plateau (days 16, 18 and 20). Cell counts (x103) from 3 different CB samples,  






























Table S2. Genes showing statistically significant difference in the levels of  





























































Table S3.  List of the antibodies used for flow cytometry. (From 37). 
 
Antibody used Clone Company Antibody used Clone Company 
CCR2/PE K036C2 BioLegend CD45RA/PE-Cy7 HI100 BD  
CCR7/Fitc G043H7 BD  CD45RA/BV510 HI100 BioLegend 
CCR7/PE G043H7 R&D CD49d/PE 9F10 eBioscience 
CCR7/BV605 G043H7 BioLegend CD62L/PE DREG-56 BD  
CCR9/PE-Cy7 L053E8 BioLegend CD62L/PE DREG-56 BD  
CD11a/PE HI111 BD  CD69/eFluor 450 FN50 eBioscience 
CD11b/PE ICRF44 BD  CD70/APC 113-16 BioLegend 
CD120b/APC 22235 R&D CD8/Fitc SK1 BD  
CD122/APC TU27 BioLegend CD8/Pacific Blue RPA-T8 BD  
CD127/PE A019D5 BioLegend CD95/APC DX2 BD  
CD14/Pacific Blue TuK4 Invitrogen CXCR3/APC 1C6/CXCR3 BD  
CD14/PerCP 134620 R&D CXCR4/APC 12G5 eBioscience 
CD16/Pacific Blue 3G8 Invitrogen gp130/PE 28126 R&D 
CD16/PerCP 245536 R&D Granzyme B/Fitc GB11 BD  
CD19/Pacific Blue SJ25-C1 Invitrogen IL-15Ra/PE JM7A4 BioLegend 
CD19/PerCP 4G7-2E3 R&D Integrin b7/PE 473207 R&D 
CD25/APC-Cy7 M-A251 BD  LT-a/PE 359-81-11 BioLegend 
CD27/APC 57703 R&D LY-9/PE hlY-9.1.25 BioLegend 
CD3/PE OKT3 BioLegend PD-1/Fitc  MIH4 BD  
CD3/V500 UCHT1 BD  Perforin/Fitc Dg9 eBioscience 
CD31/APC-eFluor 780 WM-59 eBioscience PTK7/PE 188B Miltenyi 
CD4/Fitc SK3 eBioscience TNFSF10/PE RIK-2 BioLegend 
CD44/PE BJ18 BioLegend TNFSF14/APC 115520 R&D 





















                                  
 
Fig. S1. The expression of CD27, CD45RO and CD62L in TNrev. The expression is 
shown for the cells having undergone phenotype reversion in Fig. 1A, right panel. Dashed 














      
 
 
Fig. S2. Extended phenotypic screening for putative markers of TNrev. The membrane 
expression of non-discriminatory markers of TN, recently reverted TNrev and recently 
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Adoptive T-cell therapy can be effective for Epstein-Barr virus (EBV)-associated post-
transplant lymphoproliferative disease and melanoma. Transducing high affinity TCR 
genes into T lymphocytes is an emerging method to improve potency and specificity of 
tumor-specific T cells. However, both methods necessitate in vitro lymphocyte 
proliferation, generating highly differentiated effector cells that display reduced survival 
and anti-tumor efficacy post-infusion. TCR-transduction of naïve lymphocytes isolated 
from peripheral blood is reported to provide superior in vivo survival and function. We 
utilized cord blood (CB) lymphocytes, which comprise mainly naïve cells, for 
transducing EBV-specific TCR. Comparable TCR expression was achieved in adult and 
CB cells, but the latter expressed an earlier differentiation profile. Further antigen-driven 
stimulation skewed adult lymphocytes to a late differentiation phenotype associated with 
immune exhaustion. In contrast, CB T cells retained a less differentiated phenotype after 
antigen stimulation, remaining CD57- but were still capable of antigen-specific 
polyfunctional cytokine expression and cytotoxicity in response to EBV antigen. CB T 
cells also retained longer telomeres and in general possessed higher telomerase activity 
indicative of greater proliferative potential. CB lymphocytes therefore have qualities 
indicating prolonged survival and effector function favourable to immunotherapy, 









Epstein-Barr Virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) 
complicates up to 13% of solid organ transplantation (SOT) (1). Anti-CD20 
immunotherapy is an effective first line treatment but around 40% of cases remain 
refractory. Cord blood (CB) transplantation is also associated with significant EBV and 
Cytomegalovirus (CMV) reactivation and PTLD. Adoptive cellular immunotherapy 
(ACT) using third party partially HLA-matched EBV-specific T cells is an effective 
treatment for PTLD in both settings (2-4). However, for PTLD following SOT only 50% 
respond to ACT (2) possibly because the polyspecific T cells generated in vitro using an 
EBV-transformed B-lymphoblastoid cell line (LCL) contain too few effectors specific for 
the limited set of EBV antigens expressed by the tumor. 
 An alternative approach to rapidly generate large numbers of potent and specific 
effectors is to engineer T cells to express an appropriate antigen-specific TCR or a 
chimeric antigen receptor (5, 6). This has been used successfully to treat cancers such as 
melanoma (7), where naturally occurring tumor-specific T cells are rare and of low 
avidity (8-10). Using retroviral vectors, human T cells can be reliably transduced with 
TCR genes enabling them to recognize viral or tumor antigens. Adoptive transfer of 
engineered T cells is currently undergoing clinical trials with encouraging results (11-13).  
ACT studies indicate that anti-tumor response is linked to long term in vivo persistence of 
infused cells (14-16). The factors influencing in vivo persistence of lymphocytes are not 
fully understood, but evidence suggests that the differentiation status of the T-cell is 
critical. Less differentiated naïve (TN) and central memory (TCM) T-cell subsets display 
superior proliferation, persistence and anti-tumor responses following infusion when 
compared to the more differentiated effector memory (TEM) subset (17-19). This raises an 
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important issue for ACT using genetically engineered T cells because in vitro activation 
of adult lymphocytes, required for retroviral transduction, drives the majority of 
peripheral blood-derived T cells into highly differentiated effector. Thus current 
approaches using transduced T cells may be suboptimal because the majority of cells (20, 
21) infused will be differentiated and may therefore be of limited efficacy in vivo. 
The challenge for ACT with genetically engineered T cells, or with any protocol 
involving cell expansion, is therefore to generate cells with a minimally differentiated 
phenotype. Recent studies (20, 21) suggest that CD8+ TN lymphocytes selected from adult 
peripheral blood (PB) are optimal for this purpose because, in contrast to TCM and TEM 
cells, they display minimal differentiation following TCR transduction. Human umbilical 
CB T cells, unlike adult-derived PB lymphocytes, are mostly TN. It is therefore 
reasonable to speculate whether CB might be an alternative source of T-lymphocytes for 
genetic engineering. As both solid organ and CB transplant recipients cannot access 
lymphocytes from the original donors, third party allogeneic CB is a convenient alternate 
source of lymphocytes for ACT against EBV-PTLD. Such cells can also be used in 
lymphopenic cancer patients where autologous lymphopheresis is not possible  
This study utilizes cryopreserved CB units from an unrelated cord blood bank and 
assesses the feasibility of using cord T cells to transduce EBV-specific TCR, and to 








4.3. MATERIALS AND METHODS 
 
4.3.1. CELL ISOLATION AND CULTURE. 
Frozen umbilical CB units, unsuitable for transplantation, were provided by NHSBT Cord 
Blood Bank, UK. Units were thawed in cold RPMI 1640 (Sigma-Aldrich, St. Louis, 
USA) plus 10 % fetal calf serum (FCS) (PAA, Pasching, Austria). After washing, 
mononuclear cells were isolated using Ficoll. Adult PB mononuclear cells (PBMC) were 
isolated from apheresis from healthy platelet donors (22) collected at the Blood Donor 
Centre, where the mean donor age was 42 years. The study was approved by the West 
Midlands Research Ethics Committee (05/Q2706/91). Dendritic cells (DCs) were 
generated from adherent mononuclear cells after incubating in plates for 2 hours. 
Adherent cells were cultured in medium supplemented on days 0, 3 and 6 with 50ng/ml 
GMCSF and 500 U/ml IL-4. On day 6, DCs were matured by adding 2 ng/ml IL-1β, 1000 
U/ml IL-6, and 10 ng/ml TNFα  (R&D Systems, Minneapolis, USA) (23). DCs were 
harvested after a further 24/48 hours. To confirm maturation, they were stained for CD14, 
CD83, CD86 and HLA Class II antigens. DCs were pulsed with the SSCSSCPLSK (SSC) 
peptide epitope (24) at a concentration of 10 g/ml for 2 hrs, washed and used together 
with 100 U/ml IL-2 to stimulate transduced T cells at a responder:stimulator ratio of 20:1. 
Cell counts were performed using ABX-Pentra 60 (Horiba, Kyoto, Japan). 
 
 
4.3.2. LYMPHOCYTE ACTIVATION AND TCR GENE 
TRANSDUCTION.  
CB mononuclear cells (CBMC) or PBMC, were resuspended in RPMI containing 10% 
FCS, 1% pooled human AB serum (TCS Biosciences, Buckingham, UK), 2 mM L-
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glutamine, 100 mg/ml streptomycin, and 100 IU/ml penicillin and activated with 30 ng/ml 
anti-CD3 antibody (OKT3) plus 600 U/ml IL-2 (Chiron, Emeryville, USA). Cells were 
transduced with retrovirus 48hours later. The retrovirus used was the pMP71-PRE vector 
(25) (provided by C. Baum, Hannover, Germany) into which we had inserted genes 
encoding TCR α and β chains isolated from an EBV-specific CD8+ T-cell clone that 
targets the HLA A*1101-restricted epitope SSC derived from the viral protein LMP2 
(manuscript in preparation, Zheng Y, Lee SP et al.). To generate the retrovirus, Phoenix 
amphotropic packaging cells (26) were transfected with the pMP71-PRE vector using 
FuGENE HD (Roche, Basel, Switzerland). After 48 hours the retroviral supernatant was 
harvested. Pre-activated cells were seeded at 4-6 x 106 cells/well in 1ml RPMI onto 6-
well plates coated with retronectin (Takara, Shiga, Japan). Retroviral supernatant 
(1.5ml/well) or medium alone (mock-transduced) was added to each well and centrifuged 
for 1 hour x 800g at 30oC. Medium supplemented with IL-2 (100 U/ml) was added three 
times weekly. Cells from six CB and six adult PB samples were assayed. Seven and 15 
days after transduction, T cells were stimulated with SSC peptide-pulsed DCs. Sixteen 
days after transduction, CD8+ lymphocytes were isolated using immunomagnetic beads 
(Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer’s 
instructions.  
   
 
4.3.3. FLOW CYTOMETRY. 
Transduced lymphocytes were identified using HLA A*1101:SSC peptide-specific 
pentamers (Proimmune, Oxford, UK). Cells were also co-stained with fluorochrome-
conjugated antibodies: anti-CCR7 (FITC; R&D), anti-CD4 (PerCP-Cy5.5 or PE-Cy7) 
(eBioscience, San Diego, USA), anti-CD3 (PE or APC-H7), anti-CD8 (APC or APC-H7), 
 
 142 
anti-CD27 (APC), anti-CD45RA (PE-Cy7), anti-CD62L (PE) (all from BD), and anti-
CD57 (APC; BioLegend, San Diego, CA). 7-aminoactinomycin D (7AAD from BD) was 
used as a viability marker.  
For intracellular staining, cells were fixed and permeabilized using the FIX&PERM kit 
(ADG, Kaumberg, Austria), followed by anti-Perforin FITC (eBioscience). 
For intracellular cytokine staining, cells were first stimulated with either anti-CD3 plus 
IL-2 or autologous peptide-pulsed DCs, and 1 hour later Monensin (Golgi Stop; 1 μl/ml; 
BD) was added. After overnight incubation cells were then fixed and permeabilized, and 
stained with anti-IL-2 FITC, anti-IFNγ APC and anti-TNFα PE-Cy7 (BD).  
Proliferation was evaluated by staining cells for 2 min with 1 μM carboxyfluorescein 
succinimidyl ester (CFSE) prior to activation.  
The enumeration of cells in the different phases of cell cycle or in apoptosis was 
performed using propidium iodide (PI) (27). Briefly, the cell pellet was incubated for 30 
seconds in 200μl 0.1% Triton X100 in PBS. Afterwards, the same volume of PBS plus PI 
50 μg/ml and RNAse 500 μg/ml was added, and samples were analyzed after 10 min at 
RT. Data were acquired using a FACSCanto II flow cytometer (BD). 
 
 
4.3.4. CYTOTOXICITY ASSAY  
Cytotoxicity of transduced T cells was assessed in a standard 5 hour chromium release 
assay at known effector:target ratios using 2500 target cells/well. HLA A*1101-
transduced T2 cells (28) were used as targets and were pulsed with the SSC peptide or 
another A*1101-restricted peptide epitope (IVTDFSVIK)(29) as a control. Percentages of 
specific lysis and lytic units (LU) per 106 effector cells were calculated. One lytic unit 




4.3.5. TELOMERE LENGTH MEASUREMENT  
Telomere length measurements using automated multicolor flow-fluorescence in situ 
hybridization (flow FISH) was performed by Repeat Diagnostics Inc. (North Vancouver, 
Canada). as described by Baerlocher et al. (31) 
 
4.3.6. TELOMERASE REPEAT AMPLIFICATION ASSAY  
Telomerase activity in extracts from cultured lymphocytes was measured using the 
telomerase detection assay kit (TRAPeze® telomerase Detection, Millipore) according to 
manufacturer’s instructions.  
 
4.3.7. STATISTICS 













4.4.1. ACTIVATED CB-DERIVED T-LYMPHOCYTES 
HAVE GREATER PROLIFERATIVE CAPACITY 
COMPARED TO ACTIVATED ADULT T CELLS  
 
Initially we determined the relative proportions of naive and memory T cells within CB 




/CD27+/CD45RA-/CD62L-; or TEMRA: CCR7
-/CD27-/CD45RA+/CD62L- (6).  
 
 
       
 
Figure 4.1. Lymphocytes from cord 
blood display increased proliferative 
activity in comparison to lymphocytes 
from adult blood. (A) The distribution, 
evaluated by flow cytometry, of CD4 and 
CD8 lymphocytes into TN, TCM, TEM and 
TEMRA subsets is shown for CBMC 
(white bars) and PBMC (grey bars). 
Asterisks indicate P<0.05. (B) CFSE-
stained cells were activated with anti-
CD3 plus IL-2, and proliferation was 
assessed at the indicated time points. One 
representative experiment out of six is 
shown. (C) Lymphocytes, either from 
CBMC (white bars) or PBMC (grey bars) 
were activated, and the distribution of 
cells in the different phases of the cell 
cycle was measured 48 hrs later by 
propidium iodide uptake. The percentage 
of cells in apoptosis or in different phases 
of the cell cycle is indicated. Asterisks 
indicate p<0.05.  
(From 57).    
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CCR7 and CD45RA provided sufficient discrimination among the subsets and therefore 
results based on expression of these two markers are shown hereafter. Phenotypic 
analysis confirmed that a mean of 81% of T cells in CB samples (n=6) displayed a TN 
phenotype in contrast to healthy adult blood donors (n=6) where TN constituted a mean of 
29% (Figure 4.1A). The memory cell subset within CB was comprised predominantly of 
TCM with very few TEM. 
The proliferation prior to retroviral transduction was monitored by the dilution of CFSE 
over the next 3 days.  This showed an increased proliferation rate within CB cells 
compared to adult T cells (Figure 4.1B) and was confirmed with PI staining 48 hours after 
activation which showed more than twice as many CB cells in the S to M phases of cell 
cycle compared to cells from adult donors. Importantly, this difference was not due to cell 
death as the proportion of apoptotic cells was the same in both cultures (Figure 4.1C) 
 
 
4.4.2. CORD AND ADULT LYMPHOCYTES SHOW 
COMPARABLE LEVELS OF TCR EXPRESSION 
FOLLOWING RETROVIRUS-MEDIATED GENE 
TRANSFER 
 
For the transduction of EBV-specific TCR genes, CBMC and adult PBMC were activated 
for two days and then infected with the retroviral vector encoding the TCR. Expression of 
the transduced TCR was determined using HLA-A*1101:SSC pentamers (Figure 4.2A). 
The TCR transduction efficiency was similar for both cord and adult lymphocytes (Figure 
4.2B). Pentamer staining of CB CD8+ and CD4+ T cells showed mean transduction 
efficiencies of 9.8% and 5.6% respectively whereas for adult CD8+ and CD4+ cells they 
were 10.7% and 6.1% respectively. There was no difference in the mean fluorescence 
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intensity of pentamer staining of T cells from cord or adult blood, indicating comparable 
levels of surface TCR expression (Figure 4.2C).  
 
 
                  
Figure 4.2. Cord blood lymphocytes can be transduced as effectively as lymphocytes 
from adult blood. (A) The results from a representative transduction of cord blood and 
adult blood lymphocytes with the EBV-specific TCR are shown at day 6 post-activation. 
The transduction efficiency was assessed by staining with a specific pentamer using 
mock-transduced T cells as controls. The proportions of pentamer-stained cells amongst 
CD4+ and CD8+ T-cell subsets are indicated. One representative experiment out of six is 
shown. (B) The mean percentage (+ SD) of transduced T-lymphocytes are shown for 
CBMC (n=6; white bars) and PBMC (n=6; grey bars). (C) The mean fluorescence 
intensity (MFI) of transduced T-lymphocytes derived from CBMC (n=6; white bars) and 
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4.4.3. TCR-TRANSDUCED CB T CELLS ACQUIRE A 
PREDOMINANTLY CENTRAL MEMORY PHENOTYPE 
 
We then explored how retroviral transduction affected the differentiation status of CB and 
adult T cells. Amongst transduced CB cells, 60% were TCM and most of the remaining 
cells were TN (Figures 4.3A,B).  
In contrast, the majority of transduced adult T cells had a TEM phenotype. This pattern 
was similar for both CD4+ and CD8+ T cells and for those T cells that failed to express 
the TCR (Figure 4.3A,B). 
 
                    
 Figure 4.3. After activation and TCR transduction, cord blood lymphocytes display 
a less differentiated phenotype compared with adult T-lymphocytes. (A) The 
expression of CCR7 and CD45RA before cells were activated with anti-CD3 and IL2 and 
then transduced compared with the same cells 6 days later. Black dots indicate transduced 
lymphocytes, grey dots non-transduced lymphocytes. One representative experiment out 
of six is shown. (B) The distribution of transduced CD4+ and CD8+ among TN, TCM, TEM 
and TEMRA subsets on day 6 is shown as mean (+ SD) percentages for CBMC (n=6; white 




4.4.4. TCR-TRANSDUCED CB CD8+ T CELLS 
PROLIFERATE AFTER EXPOSURE TO ANTIGEN BUT 
ARE LESS DIFFERENTIATED THAN ADULT T CELLS  
 
The ultimate aim of these studies would be to use TCR-transduced CB T cells in ACT. 
We therefore studied the proliferation, differentiation phenotype and cytokine production 
of such cells after prolonged in vitro culture and exposure to antigen.  
TCR-transduced CB and adult T cells were expanded using two rounds of stimulation 
with SSC peptide-pulsed autologous DCs. After 23 days of culture, both CB and adult T 
cells had expanded 50-fold with cell numbers continuing to rise (Figure 4.4A). 
Preferential expansion of transduced cells occurred so that by day 23 they comprised 50% 
of the CD8+ T-cell population (Figure 4.4B). 
 
      
 
Figure 4.4. After activation and 
transduction cord blood T-
lymphocytes proliferate as effectively 
as T-lymphocytes from adults. (A) 
Graph showing the mean (+ SD) fold 
increase in cell number of lymphocytes 
after activation with anti-CD3, retroviral 
transduction and two re-stimulations 
with peptide-pulsed DCs for CD8+ 
(continuous lines, filled symbols) and 
CD4+ (dotted lines, open symbols) T-
lymphocytes from CBMC (n=6; squares) 
and PBMC (n=6; triangles). (B) The 
expansion of transduced cells is shown 
as the mean percentage (+ SD) of 
pentamer-stained cells within CD8+ 
(continuous lines, filled symbols) and 
CD4+ (dotted lines, open symbols) T-cell 
subsets of lines generated from CBMC 





Comparing the differentiation status of transduced CB and adult T cells after stimulation 
with peptide-pulsed DCs we observed consistent differences especially within the CD8+ 
T-cell subset (Figure 4.5A,B).  
Transduced CD4+ CB T cells were initially dominated by TN and TCM, the latter twice as 
common, whilst adult T cells were dominated by equal proportions of TCM and TEM with 
minimal TN. However, following stimulation with antigen the TEM expanded markedly in 







Figure 4.5. After antigen stimulation 
TCR-transduced CBMC retain a less 
differentiated phenotype than TCR-
transduced PBMC. (A) The changes 
in phenotype of transduced and non-
transduced cells from the same culture 
are shown at two time points (day 6 
and day 23 post-activation). 
Representative data from a single 
CBMC- and PBMC-derived culture are 
shown. (B) The relative proportion of 
TCR-transduced TN, TCM, TEM and 
TEMRA cells within the CD4
+ and CD8+ 
subsets from CBMC (n=6, open 
symbols, upper panel) and PBMC 
(n=6; closed symbols, lower panel). 
Data shown are the mean percentage (+ 
SD). (C)  The mean percentage of 
transduced CD8+ lymphocytes 
expressing CD27 at the indicated time 
points is shown for CBMC (n=6; white 
bars) and for PBMC (n=6; grey bars). 
Asterisks indicate P<0.05. (D) The 
expression of CD57 on the same cell 
lines at day 13 post-activation. 
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After 16 days the final product was comparable in both cultures with means of 55-65% 
TEM cells.   
However, the differentiation status of CD8+ T cells during expansion was markedly 
different between cord and adult blood. CD8+ T cells in CB showed a memory cell 
transition that was similar to CD4+ CB T cells, with the proportion of TCM decreasing and 
TEM increasing until they dominated the population reaching a mean of 54.8% at the end 
of the culture period. Very few TEMRA were observed. In contrast, adult T cells showed a 
sharp decline in the proportion of both TCM and TEM subsets during expansion, and a 
marked increase in TEMRA which comprised a mean of 66.2% of the final product.  
At the end of the culture period, whilst 32.1% of CB CD8+ T cells retained the least 
differentiated TCM or TN phenotype, these two subsets accounted for only 5.4% of adult 
CD8+ cells. Note that only the transduced lymphocytes moved towards a more 
differentiated phenotype indicating that differentiation was driven by antigen-specific 
recognition (Figure 4.5A). Transduced CB CD8+ T cells therefore display a less 
differentiated phenotype compared to adult T cells throughout the in vitro culture period 
although this difference is not seen within the CD4+ population. 
In addition, after 23 days of in vitro expansion, CD27, a marker of less differentiated T 
cells, was expressed on 85.5% of transduced CB CD8+ cells but only 39.1% of transduced 
adult CD8+ cells (Figure 4.5C). Similarly, after 13 days of in vitro expansion, CD57, a 
marker of replicative senescence and antigen-induced apoptotic death of T cells (32), was 
expressed on only 17.8% of transduced CD8+ CB T cells but 56.9% of adult CD8+ cells 




4.4.5. TELOMERE LENGTH DYNAMICS AND 
TELOMERASE ACTIVITY IN TCR-TRANSDUCED CB 
AND ADULT T CELLS. 
 
TCR-transduced adult and CB T cells were taken at day 0 (pre-stimulation) and day 21 (4 




Figure 4.6. TCR-transduced CBMC 
have longer telomere length than 
TCR-transduced PBMC and 
generally retain elevated telomerase 
activity after antigen stimulation. (A) 
Changes in telomere length measured 
by Flow-FISH (Kb) of transduced cells 
from three CBMC and three PBMC 
cultures are shown at two time points 
(start of culture day 0 and day 21 post 
activation). (B) Corresponding 
telomerase activity from cell extracts of 
the same three CBMC and three PBMC 
cultures harvested at day 3 and day 21 
after initial antigen stimulation. Data 
shown are the total TRAP assay 
telomerase products generated (TPG) 
from 2x104 cell equivalents measured 
by densitometry and expressed as 
arbitrary units. (C) Representative 
telomerase activity gels including assay 
controls as well as enzyme heat 





Both adult and CB samples (with the exception of CB1) showed comparable rates of 
telomere length decline over 21 days of culture, consistent with expected shortening 
following cell proliferation, but telomeres were consistently longer in CB cells. 
Telomerase activity was assessed at day 3 after stimulation and again at day 21 (Figure 
4.6B, C). Two out of three CB cells maintained relatively high levels of telomerase 
activity, indicative of greater proliferative potential, whereas all adult T cells showed a 
decline in telomerase activity to relatively low levels at day 21. Interestingly CB 1 lost 
telomerase activity by day 21, and was the only sample to show an increase in telomere 
length during the culture period. 
 
4.4.6. TCR-TRANSDUCED CB T CELLS MEDIATE 
MULTICYTOKINE PRODUCTION AND ANTIGEN-
SPECIFIC CYTOLYSIS 
 
To investigate the effector function of the transduced cells we determined their cytokine 
production profile. T cells which secrete multiple cytokines are considered polyfunctional 
and this correlates with optimally functioning effector cells (33, 34). As such, the 
cultured cells were analyzed for production of IFN, IL-2 and TNF on day 1 (24-hours 
after stimulation with anti-CD3) and on day 10 (24-hours after stimulation with peptide-
pulsed DCs) (Figure 4.7A). On day 1 IFN secretion was negligible in CBMC but 
detectable in PBMC. However, after restimulation, the proportion of IFNsecreting  
CD8+ cells in both CBMC and PBMC increased to approximately half of both 
populations.  Polyfunctional CBMC secreting more than one cytokine also increased 
several fold upon restimulation, exceeding multi-cytokine secretion by PBMC. 
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Figure 4.7. TCR-transduced cord blood T-lymphocytes can secrete cytokines and 
mediate cytolytic function. (A) Intracellular staining for IFNγ, IL-2 and TNFα was 
performed 24 hours after activation with anti-CD3 (Day 1) and 24 hours after the first 
restimulation with autologous peptide-pulsed DCs (Day 10). Mean percentage plus 
standard deviation of CD8+ T lymphocytes staining for IFNγ and for the different 
combinations of cytokines are displayed for CBMC (n=3, white symbols) and for PBMC 
(n=3, grey symbols). The percentage of cells staining for all three cytokines was 
evaluated by first gating on double positive IFNγ/TNFα staining cells and then analysed 
for IL2 expression. (B) Intracellular perforin was assessed by flow cytometry on days 6 
and 23 post-activation. The percentages of perforin-positive cells are indicated. One 
representative experiment of three is shown. (C) CD8+ T-lymphocytes from CBMC (left 
panel) and from PBMC (right panel) were assayed for specific cell lysis activity against 
HLA A*1101-transduced T2 cells at the effector to target (E:T) ratios indicated. The 51Cr 
release assay was performed in the presence of an irrelevant peptide, DMSO or different 
concentrations of the cognate SSC peptide. Results show the mean % specific lysis plus 
standard deviation from 3 separate experiments. (D) The same data are expressed as 
mean lytic units with grey bars for PBMC and white bars for CBMC. 
(From 57).   
 
 
Compared to PBMC, the proportion of CD8+ CBMC secreting all three cytokines was 
significantly greater (p= 0.025). This pattern likely reflects the earlier differentiation 
phenotype of CB T cells and the need for antigen re-challenge before full effector 
function is activated. Antigenic stimulation of transduced CD8+ T cells from both cord 
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and adult blood led to increased expression of intracellular perforin (Figure 4.7B) a 
marker of cytotoxic potential. Cytotoxic function was assessed using a chromium release 
assay. Lysis of HLA-A*1101-transfected T2 cells pulsed with SSC peptide was observed 
at relatively low E:T ratios and decreased with titration of the peptide (Figure 4.7C). The 
results were expressed in equivalent lytic units (Figure 4.7D) and compared for cord and 
adult TCR-transduced CD8+ lymphocytes. Although there was a trend towards increased 
cytotoxicity with adult effector cells, reflecting the increased percentage of TEMRA and 
perforin-positive cells within this population (Figures 4.5B and 4.7B), this difference was 

















The clinical efficacy of adoptively transferred T-lymphocytes correlates with their ability 
to persist in vivo (14). Several studies indicate that in vivo persistence correlates with a 
less differentiated T-cell phenotype (7, 12, 15-17, 19, 35, 36) and more recent work 
suggests TN may be optimal in this setting, especially where retroviral transduction of T 
cells is required to engineer the appropriate antigenic specificity (20, 21). For this reason 
we studied CB as a potential source of T cells for TCR engineered effectors since the vast 
majority of these cells are TN. 
Using a protocol adopted for clinical trials (11, 12, 37) we found that retroviral 
transduction of CB and adult T cells led to comparable EBV-TCR expression (Figure 2) 
in both CD8+ and CD4+ CB T cells.  This is important, as TCR transduced CD4+ T cells 
can provide helper functions in vivo to maintain an effective CD8+ T-cell response, as 
well as mediate direct anti-tumor effects (38, 39). 
Immediately post-transduction, the differentiation phenotype of CB T cells differed from 
that of adult T cells, shifting from TN to a predominantly TCM rather than TEM phenotype. 
Moreover, phenotypic differences between the two cell sources were maintained 
throughout the in vitro culture. Within CD8+ T cells CB cells differentiated 
predominantly to TEM by day 23 whereas adult CD8
+ T cells shifted to a TEMRA 
phenotype typical of late differentiated cells. It is not clear to what extent the increased 
proportion of more differentiated T cells was due to increased proliferation of these cells 
or maturation of T cells from subsets with a less differentiated phenotype. The relative 
‘youth’ of expanded CB lymphocytes when compared to adult T cells was supported by 
reduced expression on cord CD8+ cells of CD57 , a marker of replicative senescence and 
antigen-induced apoptotic death of T cells (32). Furthermore, 85.5% of transduced CD8+ 
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CB T cells retained expression of CD27, a marker recently identified as predictive of 
clinical response following infusion of T cells to treat melanoma and CMV (15, 36). 
Telomere shortening is associated with lymphocyte differentiation eventually leading to 
senescence and apoptosis (40) and has been observed with cell culture in vitro and with 
age in vivo (41-43). Telomerase maintains telomere length and supports proliferative 
potential but cannot fully prevent telomere shortening (44). Ectopic telomerase 
expression supports extended lymphocyte proliferation in vitro (45).  In our study (Figure 
4.6), CB T cells had longer telomeres than adult T cells and this difference was 
maintained after 3 weeks of antigen-driven in vitro expansion. Similarly, in 2/3 CB 
samples, high telomerase activity was maintained over the same culture period, whereas 
this activity decreased in 3/3 adult T-cell samples. In one CB culture there was telomere 
elongation but suppressed telomerase activity at day 21. We speculate this may be related 
to a negative feedback mechanism that prevents uncontrolled telomere elongation by 
telomerase and warrants further investigation (46). Taken together, our results indicate 
that in contrast to TCR-transduced adult T-lymphocytes, CB T-lymphocytes have longer 
telomeres and generally maintain higher levels of telomerase activity during culture, 
supportive of greater proliferative and survival potential in vivo (19). 
Transduced CB cells expanded well in vitro (Figure 4.4) and were capable of multiple 
cytokine production and cytotoxic activity following antigen-specific stimulation (Figure 
4.7). Nevertheless, they expressed lower levels of perforin and, though not statistically 
significant, there was a trend towards reduced cytotoxic function in CB T cells in vitro 
when compared to adult T cells (Figure 4.7). This mirrors that seen in mouse studies 
where less differentiated T cells display reduced cytotoxic function in vitro compared 
with more differentiated effectors. However, in the same study, the less differentiated T 
cells possessed more potent anti-tumor activity in vivo probably reflecting the reduced 
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proliferative and survival potential of more differentiated cells (17). By analogy, our 
results suggest that the less differentiated CB T cells, which may have reduced cytotoxic 
function in vitro, may prove more effective in vivo than adult T cells, although further 
studies are required to confirm this. In this work HLA A11-restricted EBV-specific TCR 
was used to explore the function of TCR-transduced CB T cells, but further studies are 
required to confirm that these properties are generally applicable to any TCR. 
When we explored activation of CB T cells as a necessary step for retroviral transduction, 
we found CB T cells initially proliferated more rapidly than adult T cells (Figure 1B,C).  
This contradicts some reports that CB cells have increased propensity to apoptosis 
following activation (47, 48). It is unclear whether increased proliferation of CB cells 
reflects the differing proportions of naive and memory cells within cord and adult blood, 
or whether cord TN have a distinct response to mitogenic stimulation. Recent work 
suggests that the development of the immune system occurs in distinct waves derived 
from different stem cell populations, and that fetal lymphopoiesis differs from adult 
lymphopoiesis with enhanced proliferation after exposure to allo-stimulation (49). CB is 
at the transition between fetal and adult haematopoiesis, and the greater proliferation we 
observed in CB T cells may be a reflection of this.  
The clinical implication of this study is the possibility of CB providing potent third party 
T cells with good replicative and functional reserve for TCR engineering. Third party 
ACT is effective in transplant settings where matched donor lymphocytes are 
unavailable. Third party, partially HLA-matched EBV-specific T-cell lines have 
demonstrated safety and efficacy in eradicating PTLD following SOT with minimal 
GVHD risk (2, 3). In vitro expanded third party CMV-specific T cells have also been 
given successfully to a CB transplant patient with CMV encephalitis with no adverse 
effects (50). Immunotherapy with CB T-lymphocytes may also be appropriate for cancer 
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patients whose prior treatment with radio/chemotherapy and age-related thymic 
involution have rendered them lymphopenic with reduced numbers of TN and TCM 
subsets and CD27 expression (51, 52). Such cells may not have the capacity for in vivo 
persistence and clinical efficacy. CB T cells may also benefit patients with primary T-cell 
dysfunction and where autologous PBMC are difficult to handle ex vivo (eg. HIV-
infected blood).  Notwithstanding the potential benefits, TCR gene transfer with third 
party T cells carries significant theoretical risks. Although GVHD risk is reduced in CB 
transplantation (53, 54), introducing TCRs could induce heterologous immunity 
including the risk of graft-versus-graft effects in SOT recipients as the introduced TCR 
may display unanticipated alloreactivity to normal cells (55). The HLA A11-restricted 
EBV-specific TCR described here is not known to cross-react with other antigens, but 
some EBV-specific TCRs recognise particular alloantigens (56). Transduced cells should 
therefore be checked for reactivity to patient or transplant donor cells before infusion. 
Since TCR-transduced CB T cells may have greater proliferative capacity, fewer cells 
may need to be infused compared with adult T cells thus reducing the risk of GVHD. 
Selective enrichment of TCR-transduced T cells with HLA:peptide multimers could 
reduce the required dose still further. 
In summary, we have demonstrated that human CB lymphocytes have qualities suited for 
adoptive therapy using retrovirally-transduced T cells since they can be engineered to 
express high avidity functional TCR whilst maintaining an early differentiation 
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5.1. GENERAL CONCLUSIONS 
 
We have demonstrated in vitro that human CB CD8+ T lymphocytes are potentially better 
suited than analogous cells from peripheral blood of adult donors for adoptive therapy 
using TCR-transduced T cells, since they maintain an earlier differentiation phenotype 
that could lead to long term in vivo persistence after infusion.  
This consideration can be extended to T lymphocytes transduced with CAR, an approach 
that is increasingly used in ATCT. In this regard, EBV-specific T cells engineered with 
an anti-CD30 CAR have been generated for the treatment of HL and proved effective in a 
mouse model (Savoldo et al., 2007). Using CB as source of T lymphocytes for CAR 
transduction should allow for a longer in vivo survival of the infused cells. Indeed, it has 
been demonstrated that CB T lymphocytes after massive expansion retain a 
predominantly TCM phenotype and, after transduction of CD19-specific Cpost-thymic AR 
and IL-2 transgenes, prolong the overall survival in a mouse model of B-cell acute 
lymphoblastic leukemia (Pegram et al., 2015). 
It is of note that almost half of the CB units collected by public CB banks for HSCT are 
not suitable for transplant use, due to insufficient hematopoietic stem cells dose (Querol, 
2012). These CB units, which are currently useless, might provide an abundant source of 
T lymphocytes for ATCT.  
 It is now 30 years since the first CB transplant, performed on 6 October 1988 (Gluckman 
et al., 1989), and this approach has become a safe and dependable alternative donor graft 
source in allogeneic HSCT when better sources are not available. In particular, CB 
transplants show less graft versus host disease and better tolerance to HLA mismatches 
(Gluckman et al., 1997; Eapen et al., 2007). This implies that CB T cells are less effective 
in mounting an immune response or more tolerogenic than their adult counterpart. We 
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have demonstrated that after the activation needed for gene transduction, CB T cells 
retain a less differentiated phenotype and show a delay in displaying effector functions, 
compared to PB T cells which quickly become TEff. This delay might contribute to the 
reduced alloreactive response observed in CB transplants, and is explained with the fact 
that T cells in CB are mainly naive while those in adult PB are largely memory cells. 
However, differences exist also between TN cells from the two sources. It has been 
recently demonstrated that CD8+ TN cells are less cytotoxic than the same cells from 
adult PB and display a genetic profile biased toward the innate immune response 
(Galindo-Albarran et al., 2016). This might contribute to explain why CB transplants 
have a reduced allogeneic response, compared to transplants from adult donors. 
Moreover, the CD4+ TN pool in PB seems to be composed of two subsets, one of classical 
naive cells and one, likely resulting from the homeostatic peripheral expansion of the 
latter cells, characterised by decreased content in T cell receptor excision circles and 
reduced expression of CD31 (Kimmig et al., 2002). On our part, we found that TN 
lymphocytes from CB proved to be more effective than the same cells from PB in 
generating TNrev, demonstrating that the TN lymphocytes from the two sources also differ 
at the functional level.  On the basis of these considerations, we should regard CB T cells 
as true naïve cells and consider the phenotypically naïve cells from PB as a 
disomogeneous cell pool which encompasses true naïve cells, cells having ondergone 
homeostatic peripheral expansion, TSCM, TMNP and TNrev.  
Our results show that CB might be a better source of TN than PB in order to generate 
TNrev/SCM cells.  In this regard, the identification of the mechanism that allows for the 
reversion of the phenotype in recently differentiated memory CD8+ T cells provides a 
powerful tool for the in vitro generation of cells endowed with optimal proliferative and 
differentiative potential and therefore best suited for ATCT. Although TSCM can   be   
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generated in  vitro  from   TN  cells   without   undergoing   phenotype  reversion 
(Sabatino et al., 2016), it is not known if the co-stimuli used, i. e. IL-7, IL-21 and the 
glycogen synthase-3β inhibitor TWS119, are more or less effective than IL-2 in inducing 
a proliferative response. Indeed the comparison of the two techniques should be carried 
out, in order to identify the best method to produce TSCM-like cells. 
The quality of the infused cells is a parameter that has to be taken into account whenever 
a cell preparation is to be used for ATCT, including the products of banks for “off the 
shelf” lymphocytes. These banks provide EBV-specific T-cell lines (reviewed in 
O’Reilly et al., 2016) which, although proven effective (Haque et al., 2007; Leen et al., 
2013), might not provide the optimal in vivo persistence, due to the prolonged in vitro 
manipulation required to generate an established T-cell line. Instead, the establishment of 
a registry of  HLA-typed donors with high levels of circulating EBV-specific T 
lympocytes, as proposed in this thesis and by others  (Eiz-Vesper et al., 2012; Sukdolak 
et al., 2013), should allow for the ex vivo selection  of minimally manipulated cells, likely 
better suited for ATCT. 
 
5.2. FUTURE PERSPECTIVES 
 
Although ATCT has demonstrated its therapeutic effect, there are several fields where 
there is still space for improvement. However, an exhaustive analysis of all the possible 
developments is beyond the scope of this thesis, so I will briefly address three fields that 






5.2.1. MANIPULATING THE HOMING OF THE INFUSED 
CELLS 
 
The administration route of the infused cells can greatly affect the outcome of ATCT. 
Using an orthotopic mouse model of human mesothelioma, it was demonstrated that the 
local administration of mesothelin-specific CAR-engineered T lymphocytes had a clear 
advantage on the systemic route, which required many more cells to achieve the same 
remission rate (Adusumilli et al., 2014).  
An optimal homing to the tumor tissue can be better achieved by transducing the cells to 
be infused with the receptor(s) for the chemokine(s) expressed by the tumor cells. It has 
already been demonstrated, in a mouse model of HL, that CD30-specific CAR-
engineered T lymphocytes are more effective at infiltrating and killing when they co-
express CCR4 (Di Stasi et al., 2009).  
A similar approach might be followed for other chemokines. In HL the chemokine 
CXCL10 is expressed predominantly in the EBV-positive cases (Maggio et al., 2002), 
and most of NPC case express RANTES (Buettner et al., 2007). The co-transduction of 
the respective receptors, CXCR3, and CCR1, CCR3 and CCR5 may be an option to be 
considered. 
Other possible cytokines which might be investigated are CCL17 and CCL22, which are 





5.2.2. ENGINEERING THE INFUSED CELLS TO RESIST 
THE IMMUNOSUPPRESSIVE TUMOR ENVIRONMENT 
 
Tumors escape immune surveillance by means of a number of different mechanisms 
(reviewed by Camisaschi et al, 2016), which affect, at least in part, the efficacy of ATCT. 
Strategies have therefore been envisaged to target a number of tumor-associated immune 
escape mechanisms.  
Particular interest has been focused on TGF, due to its pleiotropic effects on supporting 
tumor growth (Yang et al., 2010). It was found that transduction of T lymphocytes with a 
truncated form of the dominant-negative TGFβ receptor type II (DNR) renders the cells 
insensitive to TGFβ (Foster et al., 2008). On these basis a trial on HL and NHL was 
conducted, which demonstrated an improvement in clinical response when the EBV-
specific T cells also expressed the truncated DNR (Bollard et al., 2012). Furthermore, a 
recombinant receptor was created, encompassing the extracellular portion of the TGFβ 
receptor type II and the intracellular domain of the toll-like receptor 4. In this way, the 
transduced T cells responded to TGFβ by activating and proliferating (Watanabe et al., 
2013).  
Another approach aims at targeting the tumor-associated cells exerting an immune 
suppressive activity. Tumor-specific CD8+ T cells engineered to secrete IL-12 were 
found to re-program DCs, macrophages and myeloid-derived suppressor cells (MDSCs), 
ultimately improving ATCT in a mouse model of melanoma (Kerkar et al., 2011).  
Also granulocytes may be regarded as potential targets: they represent a significant 
component of tumor-infiltrating leukocytes in NPC, where they are recruited via release 
of IL-8 by tumor cells (Hsu et al., 2008). Although granulocytes are endowed with strong 
immune suppressive potential, in this tumor type they seem to play an anti-tumor role by 
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promoting an acute inflammatory response and providing immune stimulation, both 
mediated by tumor-derived IL-1 (Chen et al., 2012). Their role in EBV-associated 
tumors should be further investigated. 
 
 
5.2.3. COMBINING ATCT WITH OTHER TREATMENTS 
 
ATCT, used so far as single therapy, might get advantage from the association with other 
treatments, either traditional or new. 
The simplest approach consists in combining ATCT with standard chemotherapy. 
Although the results need to be confirmed in a randomized trial, a phase 2 trial on 35 
EBV-positive NPC patients showed that carboplatin plus gemcitabine in association with 
infusion of EBV-specific CTLs achieved a response rate not achieved by previous trials 
with standard chemotherapy (Chia et al., 2014). Encouraging results have also been 
attained in a mouse model by combining ATCT with doxorubicin, probably due to the 
cytotoxic effect of the drug on MDSCs (Alizadeh et al., 2014).  
A more innovative approach involves the targeting of molecules down-regulating the 
immune response, such as those involved in immune checkpoints. MoAbs directed 
against immune checkpoints are currently used in specific tumor types, and the 
association of an anti PD-1 MoAb was found to significantly increase the response to the 
anti-CTLA-4 MoAb Ipilimumab in melanoma patients (Postow et al., 2017). Nivolumab, 
an anti PD-1 MoAb, has been proposed for the treatment of HD, since in this tumor the 
expression of PD-1, and of its ligand PD-L1 as well, is often increased (Ansell, 2017). 
Actually, phase I/II trials with nivolimumab and pembrolizumab, an anti PD-L1 MoAb, 
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are under way in NPC. Noteworthy, the effect of ATCT in a mouse tumor model was 
enhanced by the concomitant administration of an anti-PD-1 antibody (John et al., 2013).  
Improved therapeutic effects might be obtained using drugs targeting single molecules 
involved in tumor growth. In a xenograft model of BRAF-mutated human melanoma, the 
B-Raf inhibitor PLX4720 enhanced the effect of ATCT, likely reducing the production of 
vascular endothelial growth factor by tumor cells (Liu et al., 2013). In a similar 
melanoma model the effect of ATCT was improved by the administration of the colony 
stimulating factor 1 inhibitor PLX3397, which blocked the recruitment at the tumor site 
of M2 macrophages and MDSC (Mok et al., 2014).  
An alternative strategy might aim at making EBV-associated malignancies more sensitive 
to ATCT via the induction of the expression of immunodominant epitopes, which are a 
prerogative of lytic cycle antigens not expressed in type1 and type 2 latency tumors.  
Butyrate derivatives induce the expression of lytic antigens in LCLs and, in combination 
with ganciclovir, induced partial or complete remission in 10 out of 15 patients with 
EBV-positive lymphomas refractory to conventional therapy (Perrine et al., 2007). 
Moreover, it has been found in needle aspiration specimens from BL patients that 
treatment with cyclophosphamide results in the expression of lytic genes in tumor cells 
(Tang et al., 2010). It might be worth thinking of a trial combining these drugs with 
ATCT. 
In perspective, the use of microRNAs for enhancing and fine tuning the activity of 
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